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Screening for HLA specific antibodies is an important part of laboratory 
testing for transplantation. The conventional technique for screening is complement 
dependent lymphocytotoxicity. The development and increasing use of the sensitive 
flow cytometric crossmatch technique has meant that this conventional screening 
method is often less sensitive than the final crossmatch. The aim of this study was the 
development of a flow cytometric screening technique which would be as sensitive as 
the flow cytometric crossmatch and the investigation of the newly developed ELISA 
screening method PRA-STAT. These methods were used to investigate antibody 
production in patients with failed transplants. 
Flow cytometric analysis of antibody binding to pooled cells was found to be a 
reliable and sensitive method for the detection of HLA class I and class II specific 
antibodies. PRA-STAT also detects both class I and class II specific antibodies. Both 
flow cytometric and PRA-STAT screening methods were shown to be more sensitive 
than conventional cytotoxic screening. 
Screening of patients with failed transplants by these sensitive methods 
showed that the majority of patients produce both HLA class I and class II donor 
specific antibodies following failure of a primary transplant. Flow cytometric and 
PRA-STAT screening detected antibody production earlier than cytotoxic screening in 
some patients. HLA matching was shown to be related to both graft survival and to 
the levels of antibody produced following graft failure with poorly matched grafts 
resulting in higher levels of sensitisation than well matched grafts. Patients with 
detectable post graft failure antibodies had a lower chance of receiving a second 
transplant and had significantly worse regraft survival than patients with no antibody. 
The results of the study suggest that HLA class II specific antibodies and repeat class 
II mismatches may be detrimental in regrafts and this requires further study. 
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CHAPTER 1 
INTRODUCTION 
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The first seriously reported experiments attempting renal transplantation were 
performed in the early years of the 20th century by Emerich Ullmann who reported 
the successful autotransplant of a dog kidney from the normal position into the neck 
where it did produce some urine in 1902. A number of workers continued to 
investigate transplantation in animals and in a small number of human kidney 
xenografts were performed but such grafts never functioned for any longer than one 
hour (Hamilton 1994). The surgical techniques necessary for performing transplants 
were established during this period but interest in clinical transplantation faded. 
During the 1920's, 30's and 40's studies into the immunological nature of 
graft rejection were carried out in tumours and skin grafts and the work of Gorer, 
Snell and Medawar laid the foundations upon which modem transplantation was built 
(Brent & Sells 1989). Eventually the first partially successful renal transplant was 
performed by Hufnagel et al in 1946 when a cadaveric kidney was transplanted to the 
arm of a patient with septicaemia and anuria (reported in Moore 1964). The kidney 
functioned for a short time but was rejected within 3 days, however the patient's own 
kidneys had recovered function by that time and the patient survived (Brent & Sells 
1989). 
During the early 1950's a number of workers carried out isolated human renal 
transplants which generally failed to function for any length of time although there 
was some degree of survival of the transplanted kidney, thought to be due to the 
immunosuppressed nature of the uraemic patient (Hamilton 1994). Finally in 1954 
the first truly successful renal transplant was performed by Murray and others in 
Boston, U. S. A. when they transplanted a kidney from an identical twin into the patient 
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(Merrill et al 1956). This graft functioned for several years. A number of transplants 
between identical twins followed. 
Renal allografts from non-identical donors were attempted at this time but 
generally failed to function for any length of time. Attempts at immunosuppression 
were made using total body irradiation but this resulted in only a few isolated cases of 
successful transplantation (Hamilton 1994). It was the discovery by Calne in 1960 of 
the immunosuppressive effect of 6-mercaptopurine, allowing successful 
transplantation in dogs, which introduced the era of effective immunosuppression for 
transplantation. A derivative of 6-mercaptopurine, azathioprine was used by Caine 
and Murray in dogs and was found to be a better immunosuppressive agent (Caine et 
al 1962). Murray et al (1963) used azathioprine for human recipients resulting in the 
first long term survival of non-identical renal allografts. Renal transplantation as a 
treatment for renal failure began to be increasingly used with azathioprine and steroids 
being used for immunosuppression. The developments in tissue typing which were 
made during the 1960's (covered in section 1.7) helped to increase the success of 
clinical transplantation. 
During the 1970's the improvement in graft survival rates did not rise as 
quickly as had been hoped. A major advance however occurred towards the end of the 
decade with the discovery of the fungal metabolite Cyclosporin A (Borel et al 1976). 
Caine performed the first trials of Cyclosporin in human renal allografts and 
demonstrated improved graft survival compared with the conventional 
immunosuppression at that time (Caine et al 1978). The introduction of Cyclosporin 
throughout transplant centres followed during the early 1980's resulting in a marked 
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increase in graft survival and renal transplantation has become recognised as the 
treatment of choice for renal failure. 
The term isoantibody was first used by Bordet in 1898 (Grabar 1987) who 
observed agglutination of red blood cells by serum from rabbits which had earlier 
been injected with red blood cells. The discovery of factors in the serum of guinea 
pigs sensitised by injection of lymph node preparations from rabbits and rats which 
caused agglutination and lysis of lymphocytes was made by Metchnikoff in 1899 
(Brent and Sells 1989). The subsequent isolation of pure antibodies by Heidelberger 
and Kendall in 1936 (Graber 1987) paved the way for subsequent studies which 
elucidated the nature of antibodies. 
Antibodies are serum proteins, produced by plasma cells, which specifically 
bind the antigen which induced their production. In addition B cells carry surface 
bound immunoglobulin which acts as a receptor. The binding of antibody to the target 
antigen may bring about the removal of the target by a number of methods. Bound 
antibody may fix complement and lead directly to cell lysis or may trigger cell 
mediated responses by Fc receptor bearing cells. (Baldwin et al 1986, Whitley et al 
1990). 
The antibody molecule, or immunoglobulin, is composed of 2 identical heavy 
and 2 identical light chains. These are joined together by di-sulphide bonds, with a 
hinge region such that the antibody can be schematically represented as aY shaped 
molecule. The heavy chain contributes to the `stem and arms' of the molecule and the 
light chain to the `arms'. The regions of the light and heavy chains at the tip of the 
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molecule are areas of considerable sequence variation and it is this variation which 
leads to the multiplicity of individual immunoglobulin molecules which each 
recognise different target antigens (Roitt 1988). 
There are 5 classes of immunoglobulin in man, IgG, IgA, IgM, IgD and IgE, 
these classes are based on the structure of the heavy chain. IgG comprises the largest 
proportion of circulating antibody, around 80% of total immunoglobulin. IgA and 
IgM account for most of the rest of the circulating antibody with less than 1% of total 
immunoglobulin being IgD and IgE. IgG, IgA, IgD and IgE exist as single peptide 
units whereas IgM is a pentamer of the basic peptide unit (IgA is also found as a 
dimer). IgM and IgG are the immunoglobulin classes which cause complement 
fixation by the classical pathway, with IgM being the most effective complement 
fixing antibody. There are 4 subclasses of IgG immunoglobulins, IgGl, IgG2, IgG3 
and IgG4. The effectiveness of the subclasses at fixing complement varies, with IgGi 
and IgG 3 being the most efficient, IgG2 less so and IgG4 being non-complement 
fixing (Roitt et al 1985). 
The ability of bound antibody to fix complement is dependent on both the 
antibody class and concentration and on the antigen density (Whitley et al 1990). A 
single pentameric IgM molecule needs to bind to a number of antigenic sites so that 
the conformation of the molecule alters such that the Fc portions of the molecule are 
exposed and can initiate complement fixation (Baldwin et al 1986). For IgG 
antibodies to fix complement efficiently binding of 2 molecules in close proximity is 
necessary (Whitley et al 1990). The phenomenon of antibody mediated damage to 
transplanted kidneys is covered in section 1.4. 
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The production of antibodies directed against antigens of the major 
histocompatibility complex (MHC) following tissue transplantation was first 
described by Peter Gorer. The discovery of antigens forming part of the MHC was 
made by Gorer through his work on the transplantation of tumours in mice. He 
showed that erythrocytes from different strains of mice possessed different antigens as 
detected using sera from immunised rabbits. Transplants of tumours from mice 
possessing `Antigen IF into mice lacking this antigen showed that the tumours 
regressed, leading to Gorer's conclusion that antigenic differences between strains 
could lead to resistance to the tumour (Gorer 1937). As part of this work the animals 
which proved resistant to the transplanted tumours were bled and their sera was shown 
to specifically agglutinate cells possessing antigen II. The discovery of antigen II and 
the `iso-agglutinins' was the start of the unravelling of what was to become known as 
the MHC. 
It was almost 20 years later that Dausset described serum alloantibodies 
reacting with human leukocytes (Dausset 1958). This began the investigation of the 
human leukocyte antigen system (HLA) and the development of tissue typing which 
progressed rapidly over the next 10 years, by which time the importance of the HLA 
system in clinical kidney transplantation was becoming clear. 
The association of pre-existing antibodies with hyperacute rejection of renal 
allografts was described by Kissmeyer-Nielsen et al in 1966. Two cases of patients 
whose transplanted kidney stopped working within 1 hour of engraftment were 
described. Both recipients were shown to have antibodies which reacted strongly with 
both leukocytes and kidney extracts from their respective donors. These antibodies 
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were present in serum collected prior to transplantation. Similar findings were made 
by Williams et al (1968). In seven cases of rejection (at least 6 of which could be 
described as hyperacute) antibodies reacting with donor cells were found in the pre- 
transplant sera of 6 patients. The remaining patient received an ABO incompatible 
graft whose rejection may be attributed to anti-blood group antibodies. 
In these studies antibodies were detected by agglutination assays, although 
Williams (1968) had, in addition, employed a cytotoxicity technique developed by 
Terasaki, initially for use as a method for typing for HLA antigens. In addition to 
typing HLA antigens Terasaki was also using his cytotoxicity technique to look for 
antibodies in transplant recipients (Morris et al 1968). A large number of serum 
samples from over 40 transplant recipients were tested against a panel of 10-40 
lymphocytes. A higher proportion of patients were shown to have cytotoxic 
antibodies following transplantation than pre-transplant, with 9 of 10 cases of graft 
loss leading to antibody production. This method of screening for HLA specific 
antibodies became the standard technique used by tissue typing laboratories and, with 
some refinements, is still the most common method of antibody detection in use 
today. 
The critical importance of pre-existing antibodies to renal allografting was 
emphasised by Patel and Terasaki in 1969. In this study patients had been screened as 
previously described (Morris et al 1968). Immediate rejection was seen in 42.5% of 
recipients with pre-formed antibodies as compared to only 2.4% of those with no 
detectable antibodies. The patients with pre-formed antibodies had crossmatch tests 
carried out with donor lymphocytes and it was found that 80% of those with positive 
crossmatches lost their grafts (14.8% of negative crossmatch grafts failed). In 
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conclusion the authors stated that `The ethics of transplanting kidneys ....... across a 
known positive crossmatch result, can reasonably be expected to be questioned'. This 
was accepted by the transplant community and pre-transplant crossmatching became a 
routine requirement. Thus hyperacute rejections due to pre-formed antibodies were 
largely avoided. However elucidating the role of antibodies in transplantation and the 
difficulties associated with finding suitable grafts for patients with pre-formed 
antibodies are problems which have still to be fully solved. 
The association of preformed antibodies with hyperacute rejection of renal 
allografts found by a number of studies suggested that the antibodies played a primary 
role in the mechanism of rejection. The role of antibodies produced following 
transplantation in subsequent rejection episodes (both acute and chronic) is less clear. 
The mechanism of hyperacute rejection is the most clearly understood. 
Circulating antibodies which bind to the HLA (or blood group) antigens of the donor 
expressed on the endothelial cells of the allografted organ cause activation of the 
complement system which can lead to direct damage of the endothelial cells and to 
cell lysis. The histologic examination of hyperacutely rejected kidneys shows 
accumulation of granulocytes and platelets with coagulation leading to formation of 
microthrombi. The vessels become obstructed by thrombi leading to ischaemia and 
finally necrosis of the graft tissue (Porter, 1976). 
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The direct involvement of antibodies has been shown by 
immunohistochemical studies. Williams et al (1968) showed deposition of IgG in the 
capillaries of 4 hyperacutely rejected kidneys, 3 due to HLA specific antibodies and 1 
case of blood group incompatibility. Hyperacute rejection has also been demonstrated 
when kidneys have been perfused with an antibody containing perfusate. Cross et al 
(1974) described 2 cases of hyperacute rejection of a pair of kidneys which were 
perfused with cryoprecipitated plasma. Subsequent screening of the plasma showed a 
specific antibody directed against an HLA antigen present on the perfused kidneys. 
The importance of the specificity of the antibody for the donor antigen was 
demonstrated by the fact that a second pair of kidneys, not bearing the relevant 
antigen, perfused by the same plasma were not rejected. 
1.4.2 Acute Rejection 
Acute rejection is generally regarded as primarily mediated by the lymphocyte, 
particularly the T cells and most current immunosuppressive protocols are aimed at 
suppressing the T cell response to the allografted tissue. In cellular rejection 
lymphocytes, macrophages and granulocytes are seen infiltrating the graft tissue 
during the course of rejection (Tilney et al 1979, Tilney et al 1983). However, whilst 
the principle cause of graft destruction appears to be due to specific cell lysis by 
recipient cytotoxic lymphocytes along with a non-specific inflammatory response 
(Hayry, 1984, Chandler & Passaro 1993), there is also evidence of antibody production 
in cases of acute rejection. Whether the antibody is directly involved in graft 
destruction or is simply a consequence of the cellular immune response to the 
allogenic tissue is not clear. 
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Porter (1976) described `acute humoral rejection' where early onset of graft 
failure was accompanied by the appearance of antibodies specific to donor HLA 
antigens, although in most cases this was accompanied by some degree of lymphocyte 
infiltration. The involvement of both cellular and humoral immune responses in renal 
allograft loss was shown by Tilney et al (1979). Viable lymphocytes recovered from 
rejected grafts were shown to specifically lyse donor cells, with the principle 
component of the infiltrate being T cells in 9 of the 10 cases studied. In addition to 
this evidence of donor specific cellular activity within the graft, donor specific 
antibodies were eluted from 4 of the kidneys and immunoglobulins were 
demonstrated in the vessel walls of 3 of the kidneys. In 1982 the same group 
demonstrated the presence of immunoglobulin secreting plasma cells amongst the 
infiltrating cells recovered from a number of failed renal allografts (Garovoy et al). 
Thus whilst T cells may be regarded as the main cause of acute graft loss there 
is evidence of humoral responses taking place within the graft alongside the cell 
mediated events, emphasising that the immune response has many different effector 
mechanisms, more than one of which may be involved in the same process. 
Whilst the production of antibodies may be secondary to the cellular immune 
response it is also possible that they may initiate cell mediated graft damage by the 
mechanism of antibody dependent cell-mediated cytotoxicity (ADCC). In ADCC 
antibody bound to antigen on the allogeneic cell surface may lead to cell lysis by Fc 
receptor positive cells such as natural killer cells or macrophages. Graft infiltrating 
cells have been shown to mediate cellular lysis of antibody coated cells by Strom et al 
(1977) and Tilney et al (1979) demonstrated that antibodies eluted from rejected grafts 
had ADCC activity to donor cells. 
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1.4.3 Chronic Rejection 
Whilst the proportion of allografts lost during the early post transplant period 
has decreased over the years the attrition rate over the long term has not changed. 
Chronic rejection is a major cause of long term graft failure (death with function being 
the other principle cause of loss). Chronic rejection is a well defined process with 
specific histological and functional characteristics. The principle feature of chronic 
rejection in renal allografts is progressive thickening of vessel walls, leading 
eventually to obliteration of the lumen (Tullius and Tilney 1995, Hayry et al 1997). 
The causes of chronic rejection are not clearly understood. It is probable that a 
number of different factors are involved, both alloantigen dependent and independent. 
One factor which several studies have found to be significantly associated with the 
development of chronic rejection is the occurrence of previous acute rejection 
episodes (Almond et al 1993, van Sasse et al 1995, Opelz et al 1997). 
A hypothesis has been put forward suggesting that chronic rejection is the 
result of a continuous inflammatory process, which is the result of previous injury to 
the graft tissue (Halloran et al 1997). The association of early injury due to acute 
rejection with chronic graft failure supports this idea. The fact that allografts from 
living donors do not display the same tendency to develop chronic rejection as do 
cadaveric grafts, which may suffer injury due to the brain death of the donor or to cold 
ischaemia, also supports the theory that early damage is an important factor in the 
subsequent development of chronic rejection. 
The role of antibodies in the chronic rejection process is not understood. 
There is evidence for the involvement of endothelial specific antibodies in chronic 
rejection of cardiac allografts (Crisp et al 1994). Whether antibodies specific for 
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endothelial antigens or HLA are a factor in chronic rejection of renal allograft is not 
well documented. There have been reports linking antibodies with chronic rejection 
in renal transplantation (Mohanakumar et al 1981, Davenport 1994) but there is little 
direct evidence of antibody involvement in histologically defined chronic rejection. 
Since acute rejection episodes are associated with the subsequent development of 
chronic rejection as discussed above it is possible that early antibody mediated graft 
damage occuring during an acute rejection could predispose to chronic rejection thus 
playing an indirect role in the development of rejection. 
1.5 The HLA System & Specific Antibodies 
The human leukocyte antigen (HLA) system is coded for on the short arm of 
chromosome 6. The system is highly polymorphic and there are 2 classes of HLA 
antigens termed class I and class II with each class having several different expressed 
loci. The class I antigens were the first to be described with antigens being defined on 
the basis of serologic reactions. Early reports used differing types of nomenclature for 
the antigens being detected but by 1975 a clear nomenclature for the system was 
established with the class I loci HLA-A, B and C being described and individual 
antigens of the locus being assigned a numerical identifier e. g. Al, A2. The class II 
antigens were initially detected by cellular methods and were known as HLA-D 
antigens, but with the advent of molecular methods of HLA typing three different loci 
were identified and named HLA-DR, DQ and DP in 1984 (reviewed in Bodmer 1997). 
Some sera whose reactions were initially used to define a new HLA antigen 
were with time found not to be reactive with a single monomorphic antigen but with a 
number of different antigens which could be individually defined by reactions with 
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other sera. This led to the development of the categories of broad antigens and splits 
where for example the broad antigen originally defined as HLA-A9 was later split into 
HLA-A23 and HLA-A24 (Bodmer et al 1975), with some sera reacting with cells 
expressing either antigen but other sera being specific for only one of the 2 splits. The 
reactions of some sera with a number of different antigens also led to the recognition 
of cross reactive groups (CREGs) (Legrand & Dausset 1972 Schwartz et al 1979, 
Oldfather et al 1986). A CREG contains a number of different antigens, some of 
which may be splits of broad antigens, to which sera may be reactive although the 
stimulus for the response did not contain all of these antigens. The antigens 
comprising each CREG are determined on the basis of these serological reactions. 
CREGs are found where the different antigens have one or more structural areas 
(epitopes) in common, these are known as public epitopes, whereas the individual 
allele will possess unique, or private epitopes. 
The reactions which different sera display are determined by the HLA antigens 
present in the individual making the antibody and the HLA type of the stimulus for 
antibody production. The HLA-antigen must be recognised as foreign by the 
responder for antibody to be produced, recognition being dependant on the structure 
of the antigen. 
The HLA class I antigen consists of a polymorphic heavy chain encoded by 
the class I genes and a nonglycosylated polypeptide, ß2microglobulin. The heavy 
chain is divided into 3 domains, a-I, a-2 and a-3. The polymorphism is found within 
the a-i and a-2 domains. The structure of the HLA class I antigen was first 
demonstrated by Bjorkman et al in 1987 by X-ray crystallography of the HLA-A2 
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antigen. The a-i and a-2 domains each contribute to one of the 2 alpha helices and to 
the beta pleated sheet which form the sides and base of a peptide binding groove. 
The class II molecule consists of 2 chains, the a and 0 chains each of which 
has 2 extracellular domains. Following the elucidation of the class I structure it was 
generally believed that the a- I and ß-1 domains combined to form a peptide binding 
groove like that found in class I molecules. This was finally shown to be the case, 
with some slight differences in structure, by Brown et al in 1993. The polymorphic 
residues of the HLA-DR molecules are mainly confined to the ß chain, whereas for 
HLA-DQ molecules regions of polymorphism are found in both the a and ß chains. 
Antibodies recognise one or more epitopes of the HLA antigen. An epitope 
may be defined by a single amino acid at a specific position. Epitopes may be found 
uniquely on a single allele or, more frequently, the same epitope is found on a 
number of different alleles. The relationship of HLA antibody reactions to antigen 
structure and epitopes was first shown by Fuller et al (1990a, 1990b) who devised 
epitope maps for the HLA-A2 and HLA-B7 CREGS, identifying the positions of the 
epitopes found on all the antigens present in the CREG and on sub-groups of antigens 
or individual antigens (public and private epitopes). The majority of the epitopes 
described were found in the alpha helices of the class I molecules, although some 
were located on exposed, connecting loops. Park et al (1990) analysed a large series 
of serum screening results together with class I sequence data to determine whether 
the antibody responses observed could be explained by epitopes defined at the amino 
acid level. The results clearly showed that the patterns of antibody reactivity fitted 
those predicted by the amino acid epitopes. 
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1.6 HLA Matching in Renal Transplantation 
The importance of the degree of HLA match between donor and recipient is a 
subject which continues to generate opposing opinions. The relationship between 
HLA matching and graft outcome has been a continuing subject of investigation since 
the early years of HLA typing. In 1971 a number of studies by individual centres 
demonstrated that recipients receiving allografts with fewer mismatched antigens had 
superior graft survival when compared to those with more mismatches (e. g. 
Festenstein et al, Morris, van Rood et al). However in a large, retrospective study 
published in 1974 no significant association was found between HLA matching and 
graft outcome although there was a non-significant trend towards higher graft survival 
in better matched pairs (Opelz et al). At this time HLA typing was still in the early 
stages of development, relatively few of the antigens now known to exist had been 
identified. Therefore the matching data was necessarily incomplete. Following the 
identification of a number of DR antigens in 1977 (Bodmer et al) Ting and Morris 
(1978) retrospectively typed donors and recipients to assess DR matching and found 
that graft survival in patients matched for both DR antigens was superior to those 
matched for 1 antigen which in turn was better than those mismatched for both DR 
antigens, although with very small numbers of fully matched grafts this did not reach 
significance. This observation was followed by a study of HLA A, B and DR 
matching (Persijn et al 1978) which confirmed the stratified effect of DR matching on 
graft survival. The best survival was seen in patients with 0 or 1 DR mismatch and 
only 1 mismatch at the A or B loci indicating that both class I and class II matching 
had an effect although the DR matching was found to have the greater influence on 
graft survival. The difference in graft survival found in this study was striking with 
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87% of well matched grafts ( as defined above) functioning at 18 months as compared 
with 48% of those less well matched. 
Following the introduction of the immunosuppressive agent Cyclosporin A in 
the early 1980's, with the accompanying improvement in graft survival rates, initial 
studies showed that HLA matching did not appear to have any influence on graft 
survival in Cyclosporin treated patients (Harris et al 1985). This was refuted by the 
results of the collaborative transplant study, which showed that whilst Cyclosporin A 
treated patients did have superior graft survival compared with those on other 
immunosuppressive regimes there was still an effect of HLA matching within the 
Cyclosporin treated group (Opelz et al 1985). The study emphasised the importance 
of DR matching, with an additive effect of matching for B as well as DR. In contrast 
Lundgren et al (1986)found no effect of HLA matching in Cyclosporin treated 
patients, although there were fewer rejection episodes in the well matched patients. 
This pattern of conflicting studies has continued over the years. In general the 
large, multi-centre studies have continued to show that matching for HLA (DR and B 
especially) does have a beneficial effect on outcome (Opelz 1991, Terasaki 1991, 
Opelz et al 1993). Organ sharing schemes in Europe and the USA have used this 
premise as the basis for shipping kidneys between centres for well matched patients. 
Recent studies have investigated HLA matching in live donor transplantation. 
Two large studies have shown that recipients of kidneys from unmatched living 
donors have better graft survival than recipients of cadaveric kidneys. Jones et at 
(1994) found no difference in survival rates between completely mismatched and fully 
HLA-A, B, DR matched grafts from living related donors. Terasaki et al (1995) 
showed that allografts from unrelated living donors, which were not HLA matched, 
31 
had a survival rate comparable with that of allografts from parental donors, which are 
matched for at least one haplotype. In contrast the most recent study by Opelz (1997) 
has found a significant effect of matching for live unrelated transplants. It has always 
been the case that kidneys from living donors have had superior survival compared 
with cadaveric donor organs, most probably because very little damage is sustained by 
the kidney taken from a live donor whereas organs from cadaveric donors may be at 
risk of damage both before the organs are removed and during the storage period 
before a suitable recipient is identified and the transplant operation can take place. It 
may be that damage to cadaveric organs leads to an increased risk of recognition and 
attack by the host immune system and that this may account for a tendency for better 
matched grafts to have a lower risk of rejection than those which are poorly matched. 
However, the data published by Opelz (1997) suggests that lack of cold ischaemic 
damage in live donor kidneys does is not sufficient to completely abrogate the 
influence of HLA matching in catagory of transplants. 
The crossmatch test which identified patients at risk of hyperacute rejection 
and has remained the principle test of donor/recipient compatibility for over 25 years 
is based on the lymphocytotoxic test developed by Terasaki & McClelland in 1964 for 
the detection of antigens on human lymphocytes. A number of modifications 
following the original publication of the method were made, including the 
development of the 60 well plastic Terasaki Tray and multi-channel dispensing 
syringes, resulted in a more reproducible test which was easy to perform (Mittal et al 
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1968). The basic test involves the incubation of recipient serum with donor cells, 
followed by the addition of third party complement (usually rabbit). Following a 
further period of incubation cell viability is determined by microscopy. Any cell 
death above the background level of the negative control indicated the presence of 
complement fixing antibodies in the patients serum and is regarded as a positive 
crossmatch. This test is known as the complement dependent lymphocytotoxic (CDC) 
crossmatch and has continued to be the recommended method for HLA typing by 
serology, crossmatching and antibody screening throughout the years since its 
introduction (Dick & Crichton 1972, Darke & Dyer 1993, Martin & Claas 1993). 
A so called standard test does in theory exist and is the basic NIH CDC test 
described in the NIAID Manual of Tissue Typing Techniques. However there are 
many variations on this technique with different incubation times and temperatures 
and differences in cell/serum ratio occurring in different laboratories, the technique is 
still often referred to as the `standard technique' despite the slight deviation from the 
published version. There are also widely recognised modifications of the technique 
which are frequently used in published studies. Increased incubation times have 
frequently been used to increase the sensitivity beyond that of the standard technique 
(Ting et al 1973). The AMOS modification includes additional washing steps to 
remove unbound serum which may contain factors which inhibit complement lysis 
and therefore may increase the sensitivity compared with the standard test (Amos 
1969). The antiglobulin or AHG method employs heterologous complement-fixing 
antibodies which bind to human immunoglobulins of both complement and non- 
complement fixing classes. This allows the detection of non-complement fixing HLA 
specific antibodies as well as those which are complement fixing by a CDC assay 
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(Johnson et al 1972). The method is also more sensitive than the standard CDC 
crossmatch or CDC with extended incubation times (Cross et al 1977). The DTT 
modification of the CDC assay allows IgM antibodies to be distinguished from IgG 
antibodies. The addition of the reagent dithiothreitol to either serum or cells causes 
reduction of the di-sulphide bonds of the IgM molecules thus preventing complement 
fixation. IgG antibodies are not affected by the addition of DTT. Therefore a positive 
reaction which can be abolished by treatment with DTT can be attributed to IgM 
antibody (Chapman et al 1986, Rudy & Opelz 1987). 
The use of flow cytometry for crossmatching recipient serum with donor cells 
was first described by Garovoy in 1983. This was a single colour technique in which 
donor cells were incubated with recipient serum. Following the incubation step 
unbound serum was removed by washing steps and a second antibody, an anti-human 
immunoglobulin reagent which is conjugated to a fluorochrome was then added. 
Following a further incubation unbound secondary antibody was removed by washing 
and recipient antibody binding to the donor cells detected by single colour flow 
cytometry. Garovoy (1983) found the method to be more sensitive than CDC. In the 
early studies of the flow cytometric crossmatch (FCXM) unseparated lymphocytes 
were most commonly used, resulting in two separate populations of cells with 
different background fluorescence intensities due to the differences in 
immunoglobulin binding between T and B cells. It was therefore difficult to 
distinguish between T and B cell reactions in some tests. Some workers used 
separated T cells to overcome this problem (Thistlethwaite et al 1986). 
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The technique was further developed by Cook et al (1987) who introduced a 
second fluorochrome conjugated antibody so that immunoglobulin binding to T cells 
could be specifically determined. This was achieved by using a monoclonal antibody 
to CD3 conjugated to R Phycoerythrin (PE) in addition to an anti-human IgG 
monoclonal antibody conjugated to fluorescein isothiocyanate (FITC). Following this 
study the 2 colour FCXM has become the most popular method used. The same 
method can also be used to perform specific B cell FCXMs by the use of a CD 19 or 
CD20 monoclonal antibody conjugated to PE. (Bray et al 1989). More recently the 
development of flow cytometers has led to detectors for 3 or 4 different wavelengths 
of fluorescent emissions and it has become possible to use 3 colour flow cytometry to 
specifically label both T and B cells as well as bound immunoglobulin in a single 
reaction tube (Robson and Martin 1996). 
Analysis of the FCXM is carried out according to policies developed within 
individual laboratories and a positive FCXM may be defined by variable degrees of 
linear or logarithmic channel shift, relative fluorescence or molecular equivalents of 
bound antibody. The differences in analysis of results may lead to differences in 
definition of positivity (Harmer et al 1996). Similarly differences in methodological 
variables may also affect the result of the crossmatch (Shenton et al 1997). 
It is of great importance that any pre-formed antibodies in patients awaiting 
transplantation, whether as a result of previous failed transplant, blood transfusion or 
pregnancy are identified prior to crossmatching with a potential donor. The 
interpretation of the crossmatch test without some knowledge of the patients 
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antibodies is problematic as not all positive crossmatches are necessarily a contra- 
indication to transplantation as will be discussed in section 1.8. Knowledge of the 
level of sensitisation to HLA antigens also provides a measure of the likelihood of 
finding a crossmatch negative donor for a specific patient which can indicate whether 
a patient may have a prolonged wait for a suitable kidney to become available. 
Screening of patient's serum for pre-formed antibodies has therefore become a major 
part of the transplant laboratories work. 
The complement dependent lymphocytotoxic technique has been the standard 
test used for antibody screening throughout all transplant laboratories. The majority 
have performed the `standard' CDC test using a panel of cells to determine the 
percentage of cells against which a positive reaction is detected giving the panel 
reactivity of the sample. Analysis of the positive and negative reactions against cells 
of known HLA phenotype is carried out to determine the antibody specificity. The 
DTT modification is frequently used to distinguish between IgG and IgM antibodies. 
The accuracy of specificity determination of dependant upon the composition 
of the panel used. It is necessary for a sufficiently large number of HLA antigens to 
be represented in the panel. The antigens present should be controlled so that all those 
which might reasonably be expected to occur within the population which is being 
studied are represented. In many areas the patients requiring screening are from a 
number of different ethnic groups and the population from which potential donors 
may come will similarly comprise different ethnic groups. It can be the case that 
antigens occurring in ethnic minority groups are not always represented in the panels 
used due to the limitations in acquiring cells suitable for screening purposes. In 
addition cells expressing antigens which are present in only a small proportion of the 
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population are also difficult to obtain. The selection of a panel of cells expressing all 
the required HLA antigens is not in itself sufficient to ensure accurate specificity 
determination. It is necessary to attempt to construct the panel so that antigens of the 
different HLA loci are expressed on the cells in a variety of combinations and that 
those antigens which are commonly found in linkage disequilibrium do not dominate 
the pool in these combinations. If this does occur it becomes impossible to determine 
which of the antigens co-expressed on the cells is the target for the antibody detected. 
The analysis of the CDC test is subjective, relying upon the individual's ability 
to distinguish a significant level of cell death. Due to time constraints it is not 
practical for those who are reading the screening tray to physically count the numbers 
of live and dead cells in each individual well, therefore an estimate of the percentage 
of dead cells is generally made. The ability of each individual to estimate percentages 
will vary. In addition the percentage of dead cells which is considered significant 
varies between different laboratories. Some workers consider any cell death which is 
detectable above the background to be significant whereas others have used a cut off 
of 50% cell death to distinguish a positive from a negative reaction. Such wide 
variation in practices will inevitably lead to differences in the results obtained. 
The cells used in the panels may be freshly obtained, frozen or maintained in 
culture. Cells from freshly drawn blood of healthy individuals are likely to have the 
highest viability making it easier to detect low levels cell lysis. The use of fresh cells 
however makes the screening procedure a lengthy one. It is not possible in most 
laboratories to process the numbers of cells which would be considered necessary for 
a complete panel in a short period of time. Therefore sera are screened in batches 
with a large number of samples being collected and dispensed onto trays and then 
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screened with cells from only a few donors on each day. It can therefore take several 
weeks before the screening process is complete. 
Frozen trays have been used to avoid the delays in obtaining a final result 
(Sinnott et al 1985). In these cases the panel cells are dispensed into the wells of the 
tray and the trays are then frozen. A single serum sample can then be screened against 
the complete panel in one day. This can be a very effective method of obtaining 
results rapidly but there may be some loss of cell viability due to the freezing process 
and it also fixes and limits the panel composition. 
The use of fresh cells may enable the laboratory to have a random panel. 
Although a single panel composed of randomly obtained cells may be more limited 
than a selected panel where close attention has been given to the phenotypes of the 
cells used, the use of random panels over a period of time should ultimately lead to a 
greater number of cells of differing phenotypes being used. Thus, although screening 
of a single sample from an individual patient may not be sufficient to determine all 
possible antibody specificities, screening of serial samples over a period of time 
should provide a more complete analysis of the antibody specificities for that patient. 
Using cells derived from peripheral blood provides a population of cells which 
consists principally of T cells, indeed many laboratories use procedures to purify the 
population so that it contains almost exclusively T cells. Therefore antibodies specific 
for HLA class II antigens are not detected by this method. Peripheral blood does not 
provide sufficient quantities of B cells for testing so it is necessary to find another 
source of cells if class II screening is to be undertaken. Cells from patients with 
chronic lymphocytic leukaemia (CLL cells) are the most commonly used source of B 
cells for screening (Martin & Class 1993). However their availability is not as 
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universal as cells from healthy volunteers and many laboratories are not able to 
routinely screen for antibodies to HLA class II. The lack of agreement about the 
clinical significance of class II specific antibodies which will be discussed in the 
following sections has also meant that many laboratories have not felt it necessary to 
screen for these antibodies. 
Whereas crossmatching techniques have commonly been enhanced by 
laboratories to provide a level of sensitivity greater than that of the `standard' test this 
has not generally been the case for screening. It has been suggested that, since the 
understanding of a patient's antibody status is important for the interpretation of 
crossmatching results, the screening technique should be at least as sensitive as the 
most sensitive crossmatch test used by the laboratory (Fuller 1991). Indeed Fuller 
comments that the use of a crossmatch technique with enhanced sensitivity implies a 
lack of confidence in the screening method used. 
Since the introduction of the flow cytometric crossmatch it is the case that the 
CDC screening techniques used are likely to be significantly less sensitive than the 
final crossmatch technique. Indeed in 2 studies where flow cytometry was used to 
investigate sensitisation, rather than for direct donor recipient crossmatching, the 
method was shown to be more sensitive than CDC testing (Scornik et al1984, Rodey 
et al 1987). However, despite these indications, a method suitable for screening large 
numbers of samples by flow cytometry has not been developed. One of the aims of the 
work contained in this study has been the development of such a screening technique. 
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Since the development of the screening technique to be described in Chapter 3 
the enzyme linked immunosorption assay (ELISA) has been introduced as a method 
for the detection of HLA specific antibodies. Buelow et al (1995) described a method 
in which soluble HLA class I antigens were captured onto the bottom of the wells in a 
96 well plate using a monoclonal antibody specific for a non-polymorphic region of 
class I. HLA antigens from 46 different EBV cell lines were used. Serum is incubated 
in the antigen coated wells and then removed by washing. A peroxidase conjugated 
anti-human IgG antibody is then added, incubated and unbound antibody removed by 
washing. A chromogenic substrate is then added and colour development occurs, the 
intensity of the colour being proportional to the amount of conjugate present in the 
well. The absorbance of each well is then read using an ELISA microplate reader and 
the amount of human IgG antibody binding to the HLA antigens is determined by 
comparing the OD of the test wells with those of control wells. 
Whilst a positive crossmatch is generally regarded as a contra-indication to 
transplantation it has been clear from the first that not all positive crossmatches are 
associated with immediate failure. In Patel and Terasaki's 1969 study 20% of grafts 
with positive crossmatches did not fail, but the risk associated with transplanting 
across a positive crossmatch meant that this rarely happened when crossmatching 
became an essential pre-transplant test. 
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However, over the years many studies have looked at the significance of the 
crossmatch test and tried to find ways of determining which positive crossmatches are 
predictive of transplant failure and which are not. The main areas of investigation 
have been immunoglobulin class, T and/or B cell reactivity, autoreactivity and timing 
of positive results in relation to time of transplantation. The significance of the 
sensitising event in relation to several of the above has also been examined. 
In 1976 Cross et al first described the phenomenon of auto reactivity in 
crossmatching for transplantation. In a small series of patient's sera which gave 
positive crossmatches against donor cells were also found to be positive against the 
recipients own cells. The transplants were performed and there were no cases of acute 
graft loss. A series of reports appeared during the following year in which successful 
transplants in the face of positive crossmatches were described. Lobo et al and Ting 
and Morris (1977) found that patients with a positive B cell, but negative T cell 
crossmatch, did not reject grafts at a higher rate than those with negative T and B cell 
crossmatches. Park et al (1977) suggested that positive B cell crossmatches were due 
to auto antibodies as they found that the proportions of patients with B cell 
autoreactivity and those with reactivity to allogeneic B cells at 5°C were the same. 
Ting and Morris did not agree that all B cell reactivity was necessarily associated with 
autoantibodies and split their B cell positive crossmatches into those that were due to 
`auto' or to 'allo' reactivity. No significant difference was found between the 2 
groups in terms of graft outcome, and in fact patients with negative crossmatches had 
the poorest outcome of all in this series. Reekers et al (1977) confirmed Cross's 
observation that autoantibodies did not adversely affect graft outcome in 2 cases. In 
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contrast to these reports Dejelo & Williams (1977) described a case of hyperacute 
rejection in a patient with a positive B cell crossmatch. 
As described above B cell antibodies were often, but not exclusively, 
associated with autoreactivity. Another factor associated with autoreactivity is 
immunoglobulin class. Lobo (1981) found that autoreactivity was due to IgM 
antibody in every case tested with no evidence of IgG autoantibodies being found in 
patients on haemodialysis. The associations of these three separate characteristics has 
often led to the assumption of autoreactivity where B cell and/or IgM reactivity is 
detected and a corresponding belief that these antibodies are not deleterious to graft 
survival. 
However, closer investigation shows that the above conclusion is too 
simplistic. Some studies have clearly demonstrated that the IgM antibodies identified 
in the crossmatch test are not only reactive with the donor cells but also with the 
recipients' own cells, i. e. the antibody is an IgM autoantibody. This can be further 
confirmed by absorption of the serum with the autologous cells, leading to loss of IgM 
activity against donor (and other 3rd party cells). It is possible that some IgM 
antibodies which are not HLA specific are also not autoreactive. It is not clear how 
common this type of IgM antibody may be as not all studies have exhaustively tested 
all serum samples for both auto and 3rd party reactivity. The demonstration that 
antibody reactivity with no apparent HLA specificity is of the IgM class often leads to 
the assumption of autoreactivity without proof positive being sought. This has 
resulted in a situation where the majority of IgM antibodies are considered non- 
deleterious to renal transplants but the policy of whether to transplant in the presence 
of an IgM antibody varying between centres. Some centres consider all IgM 
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antibodies to be harmless, some require proof that the antibody causing the positive 
reaction is indeed autoreactive and some will accept that IgM antibodies with no 
evidence of HLA specificity are not a contra-indication to transplantation. IgM 
antibodies which are HLA specific are also found in some patients but there is again 
no clear consensus on whether these antibodies are deleterious to allografts. 
There has continued to be disagreement on the clinical significance of B cell 
positive, T cell negative crossmatches which are not caused by auto-reactive IgM 
antibody. Noreen et al (1987) found that aB cell positive crossmatch was associated 
with lower graft survival than the negative crossmatch group for a group of primary 
transplant recipients, although when these were split into groups receiving cadaveric 
or living donor grafts and those on different immunosuppressive protocols this 
association was no longer significant. Russ et al (1987) found an association between 
positive B cell crossmatches and rejection, the antibodies causing the positive 
crossmatch were further analysed by screening and those which were shown to have 
specificity for class II antigens were found to have the strongest association with 
rejection. Other studies have found no association between a positive B cell 
crossmatch and graft failure, indeed Hourmant et al (1990) suggested that a positive B 
cell crossmatch was associated with better outcome in regraft patients, although the 
antibody class was not determined in this study. 
The importance of determining the antibody specificity causing positive B cell 
crossmatches, as was done in the study by Russ et al (1987) has been shown in a 
number of subsequent studies. Sumitran-Karuppan et al (1990) used blocking 
antibodies to determine HLA specificity of donor reactive B cell antibodies. This 
study showed that B cell reactivity due to HLA class I specific antibody was 
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associated with poorer graft outcome than that due to class II specificity, the authors 
did however note that whilst the majority of the class I antibodies were IgG most of 
the class II antibodies were IgM. Scornik et al (1992) reported 3 cases of hyperacute 
rejection associated with positive B cell crossmatches due to HLA class II specific 
antibody. The proposal that the class II antibody was causative of the rejection in 
these cases is strengthened by the elution of class II specific antibody from the 
rejected kidney. Ten Hoor et al (1993) also showed that IgG antibodies reactive with 
donor B cells which were specific for HLA class II were associated with poor graft 
survival whereas B cell reactive IgG antibodies which were not specific for HLA or 
IgM antibodies were not. 
There is general agreement that a positive T cell crossmatch with `current' 
serum, i. e. a serum sample taken immediately prior to transplantation or the most 
recent sample obtained depending on the individual laboratories policy, is a contra- 
indication to transplantation. However the clinical significance of a positive T cell 
crossmatch with historic samples but a negative result with current serum is less clear. 
The significance of current negative, historic positive B cell crossmatches is yet more 
indistinct since there is no general agreement on the significance of current positive B 
cell crossmatches. Cardella et al (1982) first reported a number of successful renal 
transplants performed in the face of a current negative, historic positive T cell 
crossmatch in highly sensitised patients. There was no significant difference in 
actuarial graft survival between these patients and those for whom all the samples 
tested were negative. It is interesting to note that within the current negative, historic 
positive T cell crossmatch group there were 4 patients who had positive B cell 
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crossmatches with the current serum only 1 of which was still functioning at the time 
the report was published. 
Taylor et al (1989) investigated many of the factors discussed above by 
characterising the antibodies causing historic positive, current negative crossmatches 
in terms of immunoglobulin class and HLA specificity, which was determined by 
using blocking antibodies specific for HLA class I or class II antigens. In common 
with most other studies IgM, non HLA specific antibodies were not associated with 
inferior graft survival. IgM antibodies with specificity for HLA class I had no 
association with poor graft outcome if found only in historic sera but historic positive 
T cell crossmatches due to HLA specific IgG antibodies were associated with poor 
graft survival, a finding duplicated by ten Hoor et al in 1993. Taylor et al (1989) 
found that historic positive, current negative B cell crossmatches showed a different 
picture to T cells with both IgG and IgM antibodies having no association with graft 
loss in primary grafts but with poor survival in regrafts. As the antibodies were 
shown to be specific for HLA this observation raises the question as to whether the 
sensitising event is a factor for consideration. 
Sensitisation to HLA can occur due to transfusion, pregnancy or previous 
transplant. Sanfilippo et al (1982) showed that of these 3 possible sensitising events 
previous failed transplant had the greatest quantitative effect on antibody production 
as measured by the panel reactivity, with pregnancy producing an intermediate effect 
and transfusion the lowest rise in panel reactivity. When there are combinations of 2 
or more of these sensitising events for one patient this can have an additive effect on 
antibody production, Scomik et al (1984) found that blood transfusions in patients 
who had had previous pregnancies or failed grafts produced a persistent rise in panel 
45 
reactive antibody more frequently than was the case in patients with no previous graft 
or pregnancy. 
The effects of these different sensitising effects on subsequent graft survival 
was investigated by Sanfilippo et al (1982). The different effects of the combinations 
of sensitising effects were complex but it was shown that previously high antibody 
levels in transfused males, with failed grafts or transfused females with previous 
pregnancies were associated with poor outcome. High antibody levels resulting from 
transfusion alone were not associated with decreased survival compared with patients 
with no evidence of antibody production. These results indicate that sensitisation to 
previous failed grafts or pregnancy may be more harmful to subsequent grafts than 
transfusion induced antibodies. Aprile et al (1989) also found that primary graft 
recipients with high levels of peak (historic) panel reactive antibodies had similar 
survival to those with no antibody whereas regraft recipients with any significant 
antibody production fared less well than those with no antibody, supporting the idea 
that antibodies resulting from failed grafts are more deleterious to graft survival than 
those due to transfusion. 
The sensitising effect of previous transplants was also shown by Barger et al 
(1988) and Senitzer et al (1988) when regrafts which repeated HLA mismatches 
encountered on a previous graft were shown to have poor survival. Welsh et al (1988) 
however found that repeat mismatches did not increase the risk of graft loss if it could 
be shown by previous, comprehensive screening that no antibody specific for the 
mismatched antigen had ever been produced. Gnant et al (1992) also found that 
regrafts with a repeat mismatch had similar graft survival to those with no repeat 
mismatches, despite historic positive, current negative crossmatch results. Poor graft 
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survival in regrafts with repeat DR mismatches was shown by Cecka and Terasaki 
(1994) in an analysis of transplant registry data. Whilst such studies have the 
advantage of large numbers of cases there are disadvantages in that the different 
centres have a variety of different screening and crossmatch policies and the authors 
acknowledge that in many cases DR specific antibodies would not have been tested 
for and advocate the use of B cell crossmatches which are currently not performed by 
many laboratories. 
From the variety of different factors examined in many studies over the years 
it is clear that antibody specificity is a crucial factor in determining the significance of 
positive crossmatches, whether with historic or current sera. A comprehensive 
knowledge of each individual patient's antibodies to both HLA class I and class II 
antigens would provide the best basis for interpreting crossmatch results. 
The first study of flow cytometric crossmatching by Garovoy et al in 1983 
showed the method to be more sensitive than conventional CDC crossmatches for the 
detection of antibody. This was also found to be the case by Scornik et a1 in 1984 
when they investigated the relative ability of flow cytometry and CDC tests to detect 
antibody in patients prior to blood transfusion. It was found that flow cytometry 
detected antibody in a number of patients who were CDC negative and that these flow 
positive patients had a higher risk of developing persistent, CDC detectable, HLA 
specific antibodies following blood transfusion. The greater sensitivity of flow 
cytometry and the association of a positive flow crossmatch and graft rejection was 
also confirmed by Chapman et al (1985) and Thistlethwaite et al (1986) showed the 
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technique to be more sensitive than the AHG augmented CDC crossmatch as well as 
the standard method. Rodey et al (1987) demonstrated that extra reactivities detected 
by flow cytometry could be attributed to definable HLA specificities, supporting the 
possibility that positive flow cytometry crossmatches may be of clinical significance. 
In 1987 Cook et at found a clear association between a positive flow 
crossmatch and graft failure in CDC crossmatch negative renal allograft recipients. 
This association was significant only in sensitised recipients (those with previous 
failed grafts or with panel reactive antibodies). However, within the sensitised group 
the positive flow crossmatch was predicative of 50% of all graft failures. Kerman et 
al (1990) also found that a positive FCXM correlated with rejection episodes and graft 
survival in sensitised recipients as did the AHG CDC crossmatch in this study. Other 
studies demonstrated associations between positive FCXMs and complications in first 
and regrafts (Lazda et al 1988, Talbot et al 1990), long term graft survival in 
recipients pre-treated with donor specific transfusions (Bou-Habib et al 1991), and 
improved graft survival when a negative FCXM was a pre-requisite for transplantation 
(Talbot et al 1992). In contrast other studies did not find a significant association 
between a positive FCXM and graft function (Horsburgh et al 1992, Evans et al 1992) 
although the latter study did show a non-significant trend towards poor graft survival 
in the small number of regrafts studied. 
Small patient numbers in some studies may account for the lack of significant 
associations between FCXMs and outcome. In one of the largest studies of FCXM 
and primary kidney transplantation there was a significant association between a 
positive T cell FCXM and reduced graft survival at one year (Ogura et al 1993). The 
difference between the positive and negative FCXM groups was only 7 percentage 
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points, but with the large numbers was significant. It could be reasonably suggested 
that a graft survival at one year of 75% (compared with 82% in FCXM negative 
recipients) is within acceptable limits but the authors argue that as the supply of 
cadaveric organs is insufficient for the demand kidneys would be best utilised in the 
group of recipients likely to have the highest graft survival rate and therefore prevent 
`wastage' of a significant number of organs. 
All the above studies have focused on the T cell FCXM. B cell FCXMs are 
also performed by increasing numbers of laboratories. Martin et al (1993) make this 
point by describing a significant association between positive T and B cell FCXMs 
and graft failure. The demonstration of antibody binding to both T and B cells 
suggests the antibody detected is likely to be directed at the HLA class I antigens. A 
T cell positive FCXM where there is no antibody binding with B cells suggests that 
the antibody may not be HLA specific. B cell positive FCXMs may occur when the T 
cell FCXM is negative. Lazda (1994) found that a strongly positive B cell FCXM was 
significantly associated with poorer graft survival at one year compared with those 
where negative, or weakly positive, B cell FCXMs occurred. This association was 
found only in those patients receiving allografts mismatched for at least one HLA-DR 
antigen suggesting that the antibody detected may be specific for class II. The clinical 
significance of the `strongly positive' B cell FCXM as compared to that defined 
`weakly positive' emphasises the possible influence differences in methodology and 
analysis may have on determining the relevance of the positive FCXM. 
Sumitran-Karuppan (1992a) found that the FCXM could be used to great 
advantage in determining the likely outcome of renal allografts where the specificity 
of the antibody could be clearly allocated. This group had previously found that some 
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patients with weakly positive B cell CDC crossmatches could be transplanted without 
any increased risk as compared to CDC negative patients (Sumitran-Karuppan 1990). 
The FCXM study demonstrated that in the cases where the weak B cell reactions 
could be attributed to HLA specific antibodies there was an increased risk of rejection 
episodes, these patients also had a positive FCXM. A follow-up study investigated 
patients with negative CDC crossmatches but positive FCXMs and again found that if 
the antibody was HLA specific there was an increased risk of rejection (Sumitran- 
Karrupan1992b). These studies emphasise the importance of understanding the 
antibody profile of the patient serum samples when interpreting FCXMs. A screening 
technique of similar sensitivity would help in the interpretation of FCXM results. 
The relatively large proportion of patients with pre-formed antibodies detected 
by flow cytometric crossmatching who do not experience any rejection, let alone 
hyperacute rejection, recalls the earlier observation that not all cytotoxic positive 
crossmatches result in hyperacute rejection. Whilst in many cases these antibodies 
have been shown to be non-HLA specific there are still reported cases where the 
antibodies are HLA specific (e. g. Taylor et al 1987). It is clear that whilst HLA 
specific antibodies are often associated with reduced graft outcome there are 
circumstances when this is not the case. It is possible that other, recipient associated 
factors such as differences in the complement system and its regulatory mechnisms 
may affect the way in which antibodies participate in graft damaging processes. 
The de novo production of antibodies in renal allograft recipients was 
described shortly after the connection between pre-transplant HLA antibodies and 
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graft rejection was found. Morris et al (1968) looked for cytotoxic antibodies to a 
panel of lymphocytes in pre and post transplant sera and found that whilst only 4 of 21 
recipients had pre-formed antibodies at the time of transplant this proportion of 
antibody positive patients rose post transplant with 9 of 10 graft failures producing 
antibodies. They also noted that the titre of the antibodies tended to rise following 
removal of the rejected kidney. Altogether only 3 of the 17 cases where post 
transplant antibody production was observed continued to have good graft function at 
the time of publication. The results of this study clearly demonstrated that antibodies 
were produced following transplantation and suggested a possible link between such 
antibodies and poor graft prognosis. In a follow-up study the same group 
demonstrated that the antibodies produced by some patients post nephrectomy were 
directed against HLA specificities which were present on donor but not recipient cells 
(Morris et al 1969). This provided evidence that the antibody production was a result 
of sensitisation by the donor tissue and suggested the possibility that the antibodies 
may be involved in the rejection process. 
In 1978 Soulillou et al investigated the presence of antibodies in a group of 18 
renal allograft recipients. They found a significant association between the 
development of antibodies to donor B lymphocytes and early graft loss. Five patients 
experienced failure within the 1st month post transplantation, all produced antibodies 
compared with 3 of 13 patients with grafts functioning for more than 1 month. In only 
1 of the 5 cases of early graft loss were the antibodies detected prior to graft failure. 
Similarly Lepage et al (1978) detected antibodies to PBL and separated B cells in only 
3 of 9 cases of irreversible acute rejection prior to graft loss, but following transplant 
nephrectomy 3 of 4 patients with samples available for testing developed detectable 
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antibodies. The authors suggested the possibility that antibodies may have been 
absorbed onto the allograft preventing their detection in the circulation until the graft 
was removed. In this group of patients acute rejection was classed as graft loss within 
2 months of transplant. When 1 year graft survival was examined it was found that 
only 20% of transplants where B cell antibodies had been demonstrated continued to 
function compared with 68% of those with no detectable antibody. In these recipients 
the antibodies appeared prior to graft loss and it was suggested that anti-B cell 
antibodies may be prognostic of what was termed by the authors `chronic' graft loss. 
The following year the significance of anti B cell antibodies was questioned by Ting 
and Morris (1979). They failed to find any association between B cell antibodies and 
graft loss, with reactivity to donor B cells present in 63% of cases failure and 61% of 
successful transplants. 
A possible reason for the different results obtained in these studies is that the 
anti-B cell antibodies detected may have different specificities. Soulillou (1978) 
attributes the anti-B cell reactivity in the patients tested to specificity for the then 
recently described DRw antigens. The serum samples were tested both unabsorbed 
and following absorption with pooled platelets. In 2 of 5 cases there was reactivity 
with T cells which was abolished by absorption suggesting antibodies to HLA class I. 
No data is given concerning the effect of absorption on B cell reactivity and in the 2 
cases with class I antibodies additional DRw reactivity was assumed as the strength of 
the cytotoxic reaction was greater against B cells than against T cells or unseparated 
lymphocytes. However, as class I antigen expression is higher on B cells than the 
respective T cells, it is possible that these reactions could be due to the class I 
reactivity. In the study by Lapage (1978) B cell antibodies were demonstrated in sera 
52 
which had been platelet absorbed. In 50% of cases where B cell antibodies were 
found PBL antibodies which were removable by absorption were also demonstrated 
suggesting that class I specific antibodies were present in these patients. Ting and 
Morris (1979) found that there was no evidence of class I antibody in 23 of 24 cases 
where reactivity to donor B cells was demonstrated. Antibodies were shown to be 
reactive with the recipient's own B cells in 36% of patients. This highlights again the 
importance of determining the specificity of the antibodies being detected in these 
studies as in those investigating the antibodies detected by pre-transplant 
crossmatching. 
Comparison of the results of different studies on the post transplant production 
of antibodies detected using B cells can be difficult for the reasons stated above. 
However in studies which have concentrated on the role of antibodies which react 
with T cells it is possible to compare the results of studies where the specificity of the 
antibodies detected is to HLA class I. 
In 1987 Martin et al studied post-transplant antibody production in primary 
transplant recipients. Testing of serial serum samples showed that in the majority of 
cases there was no detectable antibody either pre or post transplant. The de novo 
development of antibodies was observed in 63 recipients with a reduced graft survival 
at both 1 and 5 years when compared with those recipients with no detectable 
antibody. Overall 44/63 patients lost grafts and had persistent post transplant 
antibodies. In 17 cases where a transient antibody production was observed the grafts 
continued to function. Using an exhaustive screening policy it was possible to assign 
antibody specificity from the PRA results in 26 cases and in 23 of these the specificity 
corresponded to antigens present in the donor. In only 2 cases where donor specificity 
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was demonstrated did the grafts continue to function with 21 cases of rejection. In ten 
of the failures the antibodies were detected in sera taken prior to graft failure whilst in 
11 cases the antibodies only became detectable following graft nephrectomy. 
As in the previous studies by Morris (1968,1969), Martin et al found that the 
antibodies were not always detected prior to removal of the transplanted organ. Thus 
it is unclear whether the antibody is involved in the rejection process or is merely a 
consequence of that process. In 1988 Tang et al carried out regular testing following 
transplantation using stored donor cells to detect donor specific antibody production. 
In 86.8% of cases of acute rejection there was coincident antibody production whereas 
only 7.9% of samples taken when there was no on-going rejection were found to 
contain detectable antibody. In only I case was antibody detected prior to diagnosis of 
rejection whereas samples taken on the same day as the diagnosis were positive for 
antibody. This indicates that the antibody production in these patients occurred at the 
time of rejection but was not predictive of rejection. 
A study by Halloran et al in 1992 showed a similar pattern of antibody 
production post transplant as seen by Martin and Tang. All the antibody positive 
patients experienced at least one rejection episode although antibody was detected 
prior to diagnosis of rejection in only 4 of 15 cases. The antibody was shown to 
persist in cases where rejection did not respond to treatment but reactivity disappeared 
following successful treatment. There were also rejection episodes in 41% of patients 
with no detectable antibody demonstrating that in this group of patients whilst 
antibody production was always associated with rejection, rejection was not always 
accompanied by antibody production. Whilst this study like the previous ones did not 
find antibodies predictive of rejection it did provide some evidence that the antibodies 
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were involved in the rejection process. Biopsies from antibody positive patients 
showed evidence of direct antibody mediated damage together with features of cell 
mediated damage suggesting a mixed rejection picture. In antibody negative patients 
only features of cellular rejection were seen. This suggests that the antibody is a 
participant in the rejection process although whether it initiates the rejection or simply 
contributes to a process already underway cannot be deduced. 
Lobo et al (1995) found that the outcome of rejection episodes associated with 
donor specific antibody production was poor compared to that of rejection episodes 
which were not accompanied by antibody production. As in the other studies 
described the antibody was detected at the time of onset of rejection (17 cases) or 
following graft nephrectomy (2 cases). Fifteen of the 19 patients lost their grafts 
compared with 17 of 63 with no antibody production. It is suggested that antibody 
production at the time of rejection is predictive of `poor-prognosis acute rejections'. 
Such information may be useful in determining the treatment of such rejections, 
although the cases described in this study failed to respond to aggressive treatment 
with OKT3. 
The studies described above all used complement dependent 
lymphocytotoxicity testing with either donor cells, lymphocyte panels or both. Only a 
small number of investigations of post-transplant antibody production by flow 
cytometry have been published as detailed below. 
In 1989 Scornik et al evaluated antibody production by carrying out flow 
cytometric crossmatches of post transplant serum against donor lymphocytes. 
Antibody was detected in 19 of 48 patients experiencing rejection. In 6 cases the 
antibody was of the IgM isotype only whereas IgG was present in 13. No patients 
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without rejection episodes were found to develop IgG antibodies but 2 of 22 had IgM 
production. There was a significant association between IgG antibody production and 
rejection. Once again the antibody was not detected until after the onset of rejection 
in half the cases, limiting any potential predictive value. Thus the use of the sensitive 
flow cytometric test in this study confirmed the findings of workers using CDC but 
did not confer any greater predictive value to the antibody testing. 
In contrast, Al-Hussein et al (1994) found that post transplant antibody 
production was predictive of severe rejection when flow cytometric detection was 
used. Rejections which were classed as mild were not accompanied by antibody 
production. One confounding factor was that donor specific antibodies were also 
detected in cases of delayed graft function thus it would not be possible to predict a 
rejection in a patient experiencing delayed graft function. 
Morris and Terasaki (1968) found that 9 of 10 cases of failed transplants 
resulted in the production of HLA antibodies. However since this early work very few 
subsequent studies have investigated the proportion of failed transplants which result 
in circulating HLA antibodies. In 1987 Sanfilippo investigated antibody production 
following graft failure in relation to HLA matching. This study only considered 
matching at HLA-A and B with no assessment of DR matching. The authors found 
that patients with 0 or 1 mismatched antigens had significantly lower panel reactive 
antibody levels post graft failure than those patients mismatched for 2-4 antigens. 
The better matched patients, with lower PRs were more likely to be retransplanted 
during the study period. In contrast Matas et al reported in 1990 that whilst patients 
with high PRs post graft failure had a lower probability of receiving a second 
transplant the PRs found post graft loss were not related to the number of mismatched 
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antigens at HLA-A, B, DR. The screening method used by Matas was a CDC 
technique with peripheral blood lymphocytes as the target which would be unlikely to 
reliably detect any HLA class II specific antibody production. 
HLA class II antibody production has remained a largely unexplored area, 
partly perhaps because of the lack of consensus of the clinical significance of B cell 
positive crossmatches and therefore of class II specific antibodies. The comparative 
difficulty of screening for class II specific antibodies as compared with detection of 
class I specific antibody may also be partly responsible for the smaller proportion of 
studies which have addressed this subject. 
The aim of this study is the development of a flow cytometric screening 
technique to provide a method for antibody detection which is as sensitive as the final 
crossmatch test used in the laboratory. Following successful development of this 
technique a comparative study of the flowscreen with a recently developed ELISA 
method will be carried out to determine whether the two methods are complimentary 
and could be used to gain information about antibody panel reactivity and specificity 
which standard CDC screening does not provide. Finally a combination of the 
available techniques will be used to study antibody production in patients with failed 
transplants. Graft function and antibody production will be related to HLA matching. 
The impact of antibody production on future transplantation will be investigated. 
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CHAPTER 2 
MATERIALS AND METHODS 
58 
The following list details the main reagents and consumables, and the 
suppliers, used in the techniques described in the following chapter. 
Acridine Orange (BDH 46005) 
Agarose (Sigma A-9539) 
Albumin bovine fraction V (BDH 44155) 
Ammonium Chloride (Sigma A9434) 
Antibiotic/Antimycotic solution (Life Technologies) 
Boric Acid (BDH Analar 10058) 
Bovine Haemoglobin (Sigma H2652) 
Bovine thrombin 50u (Sigma) 
BSHI Primer Kit 
Calcium Gluconate 10% w/v (Evans Medical Ltd) 
Ca! iBRITE Beads (Becton Dickinson UK Ltd) 
Complement Fixation Test diluent (ICN Flow) 
Coulter-Clenz (Coulter) 
Cystine (Sigma) 
Dimethyl Suiphoxide (Sigma) 
di-Sodium ethylenediaminetetra-acetic acid (EDTA) (BDH) 5% solution 
Ethidium Bromide (Sigma E8751) 
FITC conjugated anti-human IgG F(ab)2 (Dako Ltd F0315)) 
Foetal Calf Serum (Sigma) 
Glass Balls 2.5-3.5mm (BDH) 
Immuno-Check Beads (Coulter) 
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Isoton II (Coulter) 
Lymphoprep (Nycomed UK Ltd) 
Lyophilised Rabbit Complement (Quest Biomedical) 
Magnesium chloride (Advanced Biotechnologies) 
Park-Terasaki Medium (Life Technologies) 
Phosphate Buffered Saline (PBS) tablets (ICN Flow 28-103-05) 
PRA-STAT (SangStat Medical Corporation) 
Proteinase K (Boehringer Mannheim 1092 766) 
RPMI 1640 with Glutamax I (Life Technologies) 
Sodium Azide (Sigma S2002) 
Sodium Dodecyl Sulfate (SDS) 20% w/v (Biorad 161-0418) 
Sodium Hydrogen Carbonate (BDH Analar10247) 
tri-Sodium Citrate (BDH) 3.8% solution 
Terasaki trays (Greiner) 
Thermostable DNA Polymerase (Advanced Biotechnologies AB-0192) 
Tris-Hydrochloric Acid (Sigma T-1378) 
Ultrapure dNTPs set (Pharmacia 27-2035-01) 
IOX PCR Buffer IV (Advanced Biotechnologies AB-0289) 
0.2m1 reaction tubes (Advanced Biotechnologies AB-0264) 
1.7m1 microcentrifuge tubes (Sigma T-3406) 
6ml tubes (Falcon 2054) 
15ml tubes (Nunc 355581) 
250 cm3 culture flasks (Nunc 147589) 
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The following list details the main pieces of equipment used during this study. 
FACScan (Becton Dickinson UK Ltd) 
EPICS XL MCL (Coulter Electronics Ltd) 
Dynatech MR5000 Plate Reader (Dyantech) 
Perkin Elmer 9600 thermal cycler (Perkin Elmer) 
Heraeus Centrifuge (Heraeus) 
Microcentrifuge (Heftich) 
Electrophoresis tank (Biorad) 
Power supply (Biorad) 
UV Transilluminator (Flowgen) 
Camera (Polaroid) 
Incubator (Gallenkamp) 
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Complement dependent lymphocytotoxicity testing has been the standard 
method used for HLA typing, antibody screening and crossmatching since the start of 
tissue typing for clinical transplantstion (Terasaki & McClelland 1964). The principle 
of the assay is that HLA specific antibodies bind to the relevant HLA antigens on the 
cell surface of lymphocytes during an incubation period. Addition of rabbit 
complement after this incubation will cause lysis of any cells with antibody bound to 
surface receptors. Cell death may be visualised by staining the cells using a vital dye 
and examining by microscopy. The standard lymphocytotoxicity assay will detect any 
complement fixing antibodies but will not detect none complement fixing antibodies. 
The technique will detect antibodies other than those which are HLA specific if they 
are bound to lymphocyte surface receptors. 
All cell preparation and lymphocytotoxic testing was performed according to 
the laboratory's standard operating proceedures as detailed below. 
T cells were obtained from 20m1 of sodium citrate anticoagulated blood. The 
blood was defibrinated by incubation on an orbital mixer with 75µl of 50U thrombin, 
2ml calcium gluconate and 20 glass beads for 10 mins. The defibrinated blood was 
layered onto 4ml Lymphoprep in 15m1 centrifuge tubes and centrifuged for 15 
minutes at 1000g. The cells were collected at the interface and transferred to a clean 
tube. Ten ml of Complement Fixation Test Diluent (CFT) was added to the tube and 
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centrifuged at 400g for 5 minutes. The supernatant was decanted and the cell pellet 
resuspended in 10 ml CFT. The cells were centrifuged at 400g for 5 minutes and the 
supernatant decanted. The cells were resuspended in CFT and counted using a 
Neubauer counting chamber. The cell count was adjusted by addition of CFT to a 
final count of 1.5 - 2.0 x 106/ml. 
B cells were obtained from l Oml of EDTA or sodium citrate anticoagulated 
blood. The blood was centrifuged at 1000g for 5 minutes and the buffy coat collected 
and mixed with 1Oml PBS/citrate at 4°C. Fifteen µl of CD19 Dynabeads were added 
and mixed with the cell suspension for 5 minutes on an orbital mixer. The tube was 
placed on a magnetic particle concentrator (MPC) and left for 5 minutes to allow the 
Dynabeads and attached cells to migrate to the side of the tube next to the magnet. 
The supernatant was aspirated and the tube then removed from the MPC. The beads 
were washed twice by addition of PBS/citrate for the first wash and CFT for the 
second. The beads were resuspended in a final volume of 75µ1 CFT. 
Cadaver donor lymphocytes were obtained from a portion of spleen. A portion 
of spleen was placed in a Petri dish and CFT or RPMI added. The spleen was 
lacerated using scissors and cells were released from the spleen by gentle squeezing. 
The resulting cell rich solution was layered onto lymphoprep and centrifuged for 10 
minutes at 1000g. The lymphocytes were removed from the interface and washed 
twice by addition of CFT and centrifugation at 400g for 5 minutes. The lymphocytes 
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were resuspended in CFT, counted and the concentration adjusted to a final count of 
1.5-2.0x106/ml. If separated B lymphocytes were required 2m1 of the unseparated 
lymphocyte suspension was transferred to a clean tube and IOpl of CD19 Dynabeads 
added. The B cells were then isolated with the beads as described above. 
HLA typing of recipients was performed in the routine laboratory using 
lymphocytes separated from peripheral blood. The HLA class I type was obtained 
using T cells and the HLA class II type using B cells. Class I typing trays were made 
in the laboratory using a variety of well defined sera obtained from the United 
Kingdom Transplant Support Service Authority (UKTSSA), other Tissue Typing 
Laboratories within the UK and serum from local patients. Class II typing trays were 
commercially obtained or produced using the National sera supplied by UKTSSA. 
HLA typing of cadaveric donors was carried out using lymphocytes obtained from 
spleen. 
Cells used for antibody screening were obtained from a variety of cell donors 
including samples received for HLA typing for disease studies and local volunteers. 
HLA class I typing was performed using peripheral blood T cells. 
Serum samples were obtained regularly from patients awaiting renal 
transplantation and were stored at -20°C. Sera from patients known to have well 
defined, high panel reactive antibodies would be assigned to screening plates which 
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would be tested with 40 cells which were not from preselected cell donors but were 
randomly selected from samples received in the laboratory, termed random cells. 
Undefined sera or sera from patients known to have low panel reactive antibodies 
would be assigned to a screening plate to be tested with 60 random cells. 
Samples which required screening with DTT to identify IgM antibodies were 
set up on parallel plates one containing untreated sera and one containing sera treated 
with DTT. 
Sera for screening were dispensed into reservoir plates. A volume in excess of 
that required for the number of plates to be poured was added to each well of the 
reservoir plate. High panel reactive sera was placed in alternate wells with negative 
control sera in intervening wells. Plates were poured using the Biotest Autoseradot. 
Eight µl of paraffin oil was dispensed into each well of a 60 well Terasaki tray. One 
pl of serum was dispensed into each well. The position of each serum sample on the 
plates was recorded on the screening sheet. Screening plates were stored at -20°C. 
Sera were screened against a random panel of cells. One µl of cells was added 
to each well of the screening plate and incubated for 30 mins at 22°C. Five µl 
reconstituted, lyophilised rabbit complement was added to each well of the plate and 
incubated for 60 mins at 4°C. Cells were then stained with ethidium bromide/acridine 
orange/haemoglobin stain. 
Stock solution of stain was prepared as follows and stored as 2m1 aliquots at 
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-30°C: 
0.14g ethidium bromide 
0.07g acridine orange 
1 ml 100% ethanol 
IOOg bovine haemoglobin 
16.65g Sodium EDTA 
666ml PBS 
Plates were read by eye using an Olympus IMT2 microscope. Any dead cells 
above background were recorded with the following scores: 
up to 20% above background 1 
21-40% above background 2 
41-60% above background 4 
61-80% above background 6 
81-100% above background 8 
Individual plates were removed from the freezer and thawed prior to use. 
Plates were set up with all suitable cells received in the laboratory until fewer than 10- 
20 plates of the original 40 or 60 prepared remained to be used. The HLA types of the 
cells used so far were then checked and cells for the remaining plates were selected to 
include antigens which were missing from the panel. The percentage panel reactivity 
was determined by dividing the number of positive reactions by the total number of 
cells screened. Antibody specificity was determined by manual analysis of positive 
and negative reactions, together with information on the patient's HLA type and 
known sensitisation. 
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2.3.4.4 DTT Screening Method 
Sera for screening with DTT were treated by addition of 20µ10.1M DTT to 
180µl serum. The plates were then poured as described above. Complement to be 
added to DTT treated sera was supplemented with 25. t10. lM cystine per 1 ml 
complement. All other procedures were as described in section 2.3.4.3 
2.4 Cell Culture 
2.4.1 Cell lines 
Epstein Barr Virus transformed B lymphoblastoid cell lines were obtained 
from the European collection or UKTSSA as growing cultures. Frozen aliquots of all 
cell lines were stored in liquid Nitrogen (LN2) for future culture. All cell lines were 
grown individually as required. 
4-2 Cell Culture Method 
Cells were maintained in RPMI 1640 containing 10% foetal calf serum and 
antibiotic/antimycotic solution. Cell lines obtained as growing cultures were spun for 
5 mins at 70g. Frozen cell lines from stock were thawed by placing in a water bath at 
37°C and transferring the thawed cell suspension to Park-Terasaki medium at 37°C, 
then spun for 5 mins at 400g. The supernatant was decanted. The cells were washed 
by addition of 5ml culture medium and centrifugation. The cells were resuspended in 
culture medium to a concentration of 1x 106/ml and transferred to a culture flask. 
Growing cultures were kept at 37°C in an atmosphere of 5% CO2. Flasks were 
checked daily for cell growth and medium added as required until sufficient cells were 
present. 
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Cell pools were made by combining cells from a number of different cell lines. 
A small volume of cell suspension was removed from each flask by pipette and 
transferred to individual tubes. The cells were counted using a Neubauer counting 
chamber and the concentration calculated. The concentration and volume of each cell 
line was entered into a computer programme to calculate the amount of each cell line 
required to make the pool such that an equal number of cells from each line would be 
present. The appropriate volumes of each cell line were then pooled. In initial studies 
different numbers of cell lines were used for individual pools as detailed in figures 3.5 
and 3.6 (p117,118). Subsequently a total of 10 different cell lines were included in an 
individual pool and 2 different pools were used for all Flowscreens. 
The pooled cells were thoroughly mixed and then spun down for 5 mins at 
400g. The cells were resuspended at a concentration of 2x107/ml in a solution 
containing 45% RPMI, 45% foetal calf serum and 10% dimethyl sulphoxide. One ml 
aliquots were placed in cryotubes and the tubes placed in a freezing rack in the neck of 
a LN2 dewar. The tubes were left in the rack in the vapour phase of the LN2 for 30 
mins and then the rack was lowered so that the tubes were in the liquid. Cells were 
left in LN2 for at least 2 hours before transfer to storage in a -80°C freezer. 
Aliquots of frozen pooled cells were retrieved from storage in placed in a 
water bath at 37°C until thawed. The cell suspension was transferred to a 15m1 tube 
containing 2m1 Terasaki Park medium at 37°C and left to recover for 5 minutes. 
Pooled cells were then used in the antibody binding assay as described in section 2.5.4 
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Flow cytometry is a technique which allows measurement of a number of 
parameters for single cells using detection of light scatter and light emission. Cells in 
suspension are introduced into the flow cell of a flow cytometer via a pressurised 
fluidics system such that a narrow stream of sheath fluid surrounds the sample stream 
ensuring that cells pass through a laser beam one at a time. 
When each cell passes through the laser beam the light is scattered in a way 
which is determined by the size and density of the cell. The scattered light is detected 
by forward scatter and side scatter detectors. Forward scatter is the light scattered at 
angles close to the axis of the laser beam and is proprtional to the size of the cell. 
Side scatter is the light scattered around a 900 angle to the axis and is proportional to 
cell granularity. 
Other cellular characteristics may be measured by the use of fluorochrome 
conjugated antibodies. Membrane bound structures may be detected by addition of a 
monoclonal antibody specific for the structure of interest. If fluorochrome is bound to 
the cell surface via an antibody the fluorochrome will emit light of the appropriate 
wavelength when it passes through the laser beam. The light may then be detected by 
photomultiplier tubes. A series of filters ensures that only light of the required 
wavelength reaches the detector. The bench top flow cytometers in current use 
commonly have detectors for 3 different emission wavelengths. 
The various parameters measured for each cell as it passes through the laser 
beam are converted into electronic signals which are recorded and can be analysed by 
69 
the computer. Data which is stored as listmode data may be analysed by computers 
other than those which are part of the flow cytometer if appropriate software is used. 
The FACScan is a bench top five-parameter flow cytometer. It is fitted with a 
488nm air-cooled, argon, ion laser. Light scatter is detected by forward and side 
scatter detectors. Emissions are detected by 3 photomultipliers which detect 
fluorescein isothyocyanate (FITC) emissions via a 530nm band pass filter, 
phycoerythrin (PE) via a 585nm band pass filter and red fluoresence via a >650nm 
band pass filter. 
At the start of each daily session the machine alignment and sensitivity was 
checked using CaliBRITE beads. The amplifier gains and PMT voltages were set and 
spectral overlap compensated using the AUTOCOMP software. The instrument 
settings were recorded and a sensitivity test run and the results recorded. Forward 
scatter and side scatter measurements were carried out using a linear scale and 
fluorescence measurements made on a4 decade log scale. All flow cytometry 
performed in this study was single colour using FITC. FITC was detected by the FL1 
detector. FL2 and FL3 detectors were switched off. FITC data was collected using 
the log scale with resolution set at 256 channels. 
Cell populations were identified by the forward and side scatter profiles 
(Figure 2.1, p90). The forward scatter gain and side scatter voltage were adjusted as 
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necessary to display the population in the FSC/SSC dot plot. The cell population of 
interest was live gated so that data on that population only was stored. For each 
sample analysed 10,000 events were collected. Listmode data was stored on floppy 
disks. 
Data analysis was performed using the LYSYS II analysis software. FL1 
histograms were drawn for each sample to be analysed. An analysis gate was set on 
the negative control sample using the histogram statistics menu. The analysis gate set 
on the negative control was stored and copied to the histogram plot of each test 
sample. Histogram statistics were displayed and the percentage of events falling 
within the analysis gate was recorded. Figure 2.2(p 91) shows examples of positive 
and negative histograms with analysis gates and statistics. The percentage reactivity 
of the samples is given by the percentage of gated events. 
The EPICS XL MCL is a bench top five-parameter flow cytometer. It is fitted 
with a 488nm air-cooled, argon, ion laser. Light scatter is detected by forward and 
side scatter detectors. Emissions are detected by 3 photomultipliers which detect 
fluorescein isothyocyanate (FITC) emissions via a 525nm band pass filter, 
phycoerythrin (PE) via a 575nm band pass filter and red fluoresence via a 620nm 
band pass filter. The MCL attachment takes a carousel which allows 32 tubes to be 
run in an automated fashion. 
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At the start of each daily session the start up programme was run and the 
machine alignment and detectors checked using Immunocheck beads. If half peak 
CVs were greater than 2.0 the prime function was performed as required until the half 
peak CVs fell within the acceptable range as instructed by the manufacturers. For 
single colour analysis the FSC, SSC and FL 1 detectors were selected. Linear 
amplification was used for FSC and SSC and a4 decade log scale was used for FL! 
merasurements. The cell population was identified by forward and side scatter. A 
gate was set around the population and used to set the stop count so that 10,000 events 
falling within the gate were collected. (Figure 2.3 p92) Listmode data on all events 
was stored for initial analysis on the hard disk and following analysis was archived to 
optical disk in case subsequent analysis was necessary. 
The listmode data on all test samples in a run was selected and the negative 
control sample was replayed to give the FL 1 histogram. The analysis gate was set 
using the negative control and stored. The listmode data on all samples was then 
replayed as a batch with the analysis gate being copied to all histograms. The data 
was then displayed using the multigraph gallery command and the histograms and 
histogram statistics printed. The percentage of events falling within the analysis gate 
was recorded. Figure 2.4 (p93) shows the data print out for a series of 8 samples 
analysed in this way. 
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The principle of the flow cytometric binding assay is that antibodies present in 
human serum will bind only to the antigens for which they are specific when cells and 
serum are incubated together. Unbound antibody is removed at the end of the 
incubation period by diluting and decanting the serum using washing steps. An anti- 
human immunoglobulin specific polyclonal antibody conjugated to a fluorochrome is 
then added and will bind to any human immunoglobulin of the appropriate class 
which has bound to cell surface antigen during an incubation period. Unbound 
polyclonal antibody is removed at the end of the incubation by washing steps. The 
cells are then analysed by flow cytometry to detect bound fluorochrome on the cell 
surface. 
The cells to be used in flow cytometric techniques were all washed and 
resuspended in a solution of phosphate buffered saline containing 0.1 % bovine serum 
albumin and 0.1% sodium azide (FACS diluent). The cells to be used in the assay 
would be transferred to a 15m1 tube and the volume of liquid in which the cells were 
suspended was made up to 10ml by adding FACS diluent. The cells were spun in a 
centrifuge for 5 minutes at 400g. The supernatant was decanted and the cells 
resuspended in l Oml FACS diluent. The cells were spun in a centrifuge for 5 mins at 
400g. The supernatant was decanted and cells were resuspended in FACS diluent at a 
final concentration of 5x 106-5x 107/ml. 
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A negative control serum was included in every assay. The negative control 
was pooled normal human serum. In early assays where the flow cytometric 
screening technique was under development the negative control serum was chosen on 
the basis of cytotoxic screening results and previous satisfactory performance in flow 
cytometric crossmatches. When the flow cytometric screening technique became 
established negative control sera were selected on the basis of cytotoxicity and flow 
cytometry screening results. 
A positive control serum was included in each run. The positive control was a 
pool consisting of equal volumes of serum selected from 5 highly sensitised patients 
(panel reactivity >80%). The sera were selected on the basis of cytotoxic screening 
results such that the pool would be expected to be positive with all HLA class I 
antigens. 
All sera were stored at a temperature below -20°C and were thawed 
immediately prior to use by placing in a water bath at 37°C. 
All reactions were carried out in 6m1 tubes (Falcon). The tubes were labelled 
and the required volume of serum added to the tube (volumes varied according to the 
assay and will be detailed in each section ). The required volume of cells was then 
added and the cells mixed with the serum by vortexing for 2 seconds. Caps were 
placed on the tubes and the cells incubated for 30 minutes at 22°C. 
Unbound antibody was removed after the incubation by adding 2m1 FACS 
diluent to each tube, mixing and centrifuging at 400g for 5 minutes. The wash step 
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was then repeated. The supernatant was decanted and the cells resuspended in the 
residual FACS diluent in the tube (a volume of 30-4Oµ1). 
Four µl of a polyclonal anti-human IgG antibody conjugated with FITC was 
added to each tube. The cells were mixed by vortexing and incubated for 30 minutes 
at 4°C. 
Unbound polyclonal antibody was removed by 2 wash steps using 2m1 of 
FACS diluent and centrifuging at 400g for 5 minutes. The cells were resuspended in a 
final volume of 500 µl FACS diluent and were analysed immediately. 
The analysis gate was set on the negative control as illustrated in figures 2.2 
and 2.4. A background binding of between 0 and 10% was allowed within the analysis 
gate. The percentage of positive cells falling in the analysis gate was recorded for each 
sample. Antibody binding of 10% or greater above the background binding was 
classed as positive. 
All enzyme linked immunsorbent assays (ELISA) were carried out using the 
PRA-STAT kits according to the manufacturer's instructions. The principle of the 
test is illustrated in figure 2.5. Soluble HLA molecules are captured onto the bottom 
of wells using monoclonal antibodies and these are supplied in the form of 96 well 
plates. HLA molecules from different cell lines are used to coat individual wells. 
Serum is added to the individual wells and incubated to allow antibody binding to the 
antigens coating the well if the antibody in the serum is specific for the antigens 
present. Following this incubation the plates are washed to remove unbound antibody. 
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An anti-human IgG antibody conjugated to peroxidase is then added to each well. 
This antibody will bind to human IgG which is bound to the antigens coating the well 
but will not bind if no human antibody is present and will not bind to 
immunoglobulins of different classes. Following the incubation with the anti-human 
antibody the plates are washed to remove unbound antibody. A chromogenic 
substrate is then added to the wells and colour will develop during the incubation with 
an intensity which is proportional to the amount of bound conjugate. The reaction is 
then stopped and the absorbance of each well is measured using an ELISA reader. 
Each kit contained 6 sets of 4 plates and allows for the testing of 8 samples 
per set of plates. Each plate consisted of 8 rows (row A-H) and 12 columns. Columns 
1-12 of the assay on plate A, 13-24 on plate B, 25-36 on plate C and 37-48 on plate 
D. On plate A column 1 contained a control preparation of soluble HLA antigen, and 
column 2 had no antigen bound to the well. All the remaining columns on the 4 plates 
contained soluble HLA derived from an individual cell line, 46 cell lines in total. 
A positive reference sample containing HLA class I specific antibodies and a 
negative reference human serum with no HLA specific antibodies were provided. 
The specimen/conjugate diluent of bovine serum albumin in a stabilised buffer 
was supplied as a x4 concentrate. This was diluted 1: 4 in distilled water immediately 
prior to use. 
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The wash buffer was provided in powder form and dissolved according to the 
manufacturers instructions prior to use. 
The conjugate was a goat anti-human IgG and was supplied in lyophilised 
form. The conjugate was reconstituted by adding 1.5m1 deionised water. The 
conjugate was stored in solution at 4°C following reconstitution. 
The substrate solution was made immediately prior to use by dissolving o- 
phenylenediamine tablets in the buffer provided and placing in the dark for several 
minutes until the tablets were fully dissolved. 
The stop silution was IN hydrochloric acid. 
Each serum sample to be tested was diluted 1: 101 by adding 70gl of serum to 
7m1 specimen/conjugate diluent and mixing well. The positive and negative reference 
samples were diluted 1: 101 by adding 10µl to lml of specimen/conjugate diluent. 
l00µ1 of the positive reference was added to the wells in rows A-F of column 1 and 
100µl of negative reference was added to wells G and H of column 1.100µl of test 
serum was added to each of colums 2-48 of a single row. The plates were incubated 
for 2 hours at room temperature. 
Washing was carried out manually. The serum was removed by inverting the 
plates and flicking quickly to expel the contents of the wells. Each well was filled to 
the rim with wash buffer and the buffer then removed by repeating the flicking 
procedure. This step was repeated twice. Any excess wash solution remaining in the 
wells was removed by inverting the plates and draining onto absorbent paper. 
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The conjugate was prepared by diluting 100µl of the conjugate stock solution 
in 900µ1 of specimen/conjugate diluent. This was then further diluted according to 
the manufacturers instructions to a final dilution which was lot specific. l00µl of the 
conjugate solution was added to each well and the plates were incubated for 1 hour at 
room temperature. Following this incubation the plates were then washed three times 
as described above. 
The substrate solution was then added. A timer, set for 15 minutes, was started 
immediately following the addition of 100µl of substrate solution to row A of plate A 
and 100µd was dispensed into each subsequent row of plates A to D at a steady rate. 
The plates were then placed in the dark. At the end of the 15 minute incubation l00µ1 
of the stop solution was immediately dispensed into row A of plate A and then at a 
steady rate into the subsequent rows. 
The plates were read within 15 minutes of the addition of the stop solution 
using a Dynatech MR5000 plate reader, under computer control using the SOFT- 
STAT software. The measuring wavelength was set at 492nm with a reference 
wavelength of 620nm and the absorbance (OD) of each well was recorded using 
SOFT-STAT. 
Analysis of results was carried out using SOFT-STAT software and by manual 
analysis of the results produced by SOFT-STAT. 
The following calculations were performed by the SOFT-STAT software. 
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For a valid assay the positive references in rows A-F of column 1 should have an OD 
between 0.67 and 1.76. The mean of the 6 positive reference OD values was 
calculated. AA value was calculated for each well on the plate as follows 
A= OD test well - OD of no antigen well 
A cut off value was determined by SOFT-STAT such that: 
cut off value = mean of positive reference x 0.35 
If the 0 value for a well was greater than the cut off value that well was judged 
positive with the specimen tested. The positive/negative results for each of the 46 test 
wells were calculated for each sample. A panel reactivity was calculated as follows 
% PRA = no. positive results x 100 
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The operator could obtain results reports in formats where results were sorted 
according to OD, 0 or well no. Sorting according to 0 produced a report which listed 
the reactions of the sera with the individual wells in order of the strength of the 
reaction. Fig 2.6 (p95) shows the standard result report used in this study sorted 
according to the 0 value. The cut off value is shown at the top of the report and all 
wells with aA greater than this were reported as positive. The operator derived 
positive threshold is indicated by the line drawn below the result for well 38. It can be 
seen from the result that although wells 37,32,47 and 38 are classed negative by the 
analysis software they fall only just below the cut off. There is a larger gap in the A 
value of well 38 and well 12 where the operator derived cut off has been assigned. 
The antibody specificity was determined by Fisher's analysis. These 
specificities were confirmed or adjusted by the operator following analysis of the 
reactions with all the wells in conjunction with the HLA type of the patient from 
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which the sample was obtained and also with any HLA data relating to known 
sensitising events. In all instances the HLA specificities assigned as a final result 
were those confirmed by the operator. The operator derived cut off such as that shown 
in fig 2.6 (p95) may be confirmed by the specificity analysis. As shown in this 
example the specificity of the reactions classed negative by the analysis programme 
but positive by the operator indicates that these reactions are consistent with the A2 
specificity determined by SOFT-STAT. All results were analysed in this way and the 
PR determined by SOFT-STAT was amended by the operator where necessary. 
2.7 DNA Typing 
2.7.1 Introduction 
The HLA typing data used in this study is mostly obtained from patients' 
records and was performed by lymphocytotoxicity testing as described in section 2.3. 
However, a number of the recipients included in this study had not been HLA class II 
typed at the time they were transplanted and class II typing was not subsequently 
carried out unless the graft failed and the patient returned to the transplant waiting list. 
Therefore the typing data was incomplete and analysis of HLA matching could not be 
carried out. In order to minimise the number of cases with incomplete HLA typing 
the transplant clinic staff were requested to supply I Omi of EDTA anti-coagulated 
blood from listed transplanted patients when they were seen in the out patient clinic. 
Lymphocytotoxic typing was not considered a practical approach for these 
patients because the dates of sample receipt were not known in advance. It was 
therefore decided that DNA would be extracted from the patient's blood and stored 
until typing could be performed. 
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All DNA extraction and typing was performed according to the laboratory's 
standard operationg procedures which are based on the technique of Olerup and 
Zetterquist (1992). 
Red Cell Lysis Buffer 2m1 (4.2g sodium hydrogen carbonate in 50m1 water) 
2L distilled water 
15.4g ammonium chloride 
Nuclei Lysis Buffer 23.37g sodium chloride 
1 Oml 1M Tris-hydrochloric acid 
4m1 0.5M EDTA 
distilled water to a final volume of 1L 
Proteinase K 5m1 SDS 
400µ10.5M EDTA 
90m1 distilled water 
200mg proteinase K 
5x TBE Buffer 109g Tris-hydrochloric acid 
55.6g Boric acid 
40m1 EDTA 
Distilled water to a final volume of 2L 
(Dilute with distilled water for 0.5x working solution) 
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Deoxynucleoside triphosphate (dNTP) Mix 
2Oµ1 each of dATP, dCTP, dGTP, dTTP 
92Oµ1 sterile water 
Primer Mix 20µl left hand primer 
2Oµ1 right hand primer 
1 pl control 5' primer 
1 µl control 3' primer 
60µl double distilled water 
Agarose Gel 1Og Agarose 
IL 0.5x TBE 
50µ1 ethidium bromide (10mg/ml stock) 
The EDTA anticoagulated blood was centrifuged at 550g for 10 minutes. The 
buffy coat was then transferred to a clean 15 ml tube, mixed with 9mls of red cell lysis 
buffer and incubated for 20 minutes at room temperature. The cells were centrifuged 
at 550g for 10 minutes and the red cell lysate removed leaving the white cell pellet in 
the tube. The white cell pellet was resuspended in 3mls nuclei lysis buffer and 200µl 
SDS was added and mixed well. One hundred µd Proteinase K solution was added 
and the sample incubated for 16 hours at 37°C or for 2 hours at 55°C. 
One ml of 6M NaCl was added and mixed well and the sample was then 
centrifuged at 2700g for 30 minutes. The supernatant was removed, taking care to 
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avoid the pellet and transferred to a clean universal tube. Two volumes of 100% 
ethanol were added to the supernatant and mixed by gentle inversion of the capped 
tube. The precipitated DNA was removed from the solution, transferred to a 
microcentrifuge tube and dissolved in 100-300 µl distilled water. The DNA was then 
stored at 4°C. 
Reaction tubes were placed in a retainer. Pre-prepared primer mixes were 
used. The primer mixes were mixed and spun in a microcentrifuge prior to use. Five 
µl of primer mix was dispensed into each reaction tube. The DNA enzyme mixture 
was then prepared as follows: 
70µl double distilled water 
5µ1 DNA 
30µl IOx Buffer IV 
3Oµ1 dNTP mix 
l3µ1 MgC12 
2µl Thermostable DNA polymerase 
The DNA/enzyme mixture was mixed well and spun in the microcentrifuge. 
Five µl of the DNA/enzyme mixture were added to each of the reaction tubes 
containing the primer mixes taking care not to contaminate the mixture with any 
primers. 
The reaction tubes were capped and placed in the thermal cycler and the 
cycling programme started and run as follows: 
Heat at 95°C for 5 mins 
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30 cycles of: 
94°C - 20 seconds 
65°C - 50 seconds 
72°C - 20 seconds 
An agarose gel was poured in a gel tray and the combs positioned in the gel. 
The gel was then left to set. When ready for use the gel was submerged in an 
electrophoresis tank containing 0.5xTBE buffer and the combs carefully removed. 
The reaction tubes were removed from the thermal cycler and the caps removed. One 
µl of gel-loading buffer was added to each reaction. I Opl of 100 base-pair ladder was 
added to the first well and the middle well of each row of the gel. The reaction 
samples were then loaded into the wells taking care not to carry any sample over into 
a consecutive one. As soon as all the samples were loaded the lid was placed on the 
tank and electrophoresis started. The gel was left to run for 30 minutes, checking the 
progress of the samples through the gel to ensure no sample was lost from the edge of 
the gel. The gel was then removed from the tank and placed on a UV transluminator. 
The W source was turned on and a photograph of the gel was taken. 
The HLA type was determined by identification of amplified product of the 
appropriate size. 
84 
Statistical analysis of antibody detection was carried out in 2 different ways. 
Ability of the different tests to detect antibody was determined by comparison of 
positive or negative results for each sample tested. Comparison of different tests to 
detect the level of antibody production in positive samples was carried out by analysis 
of panel reactivities. 
Positive and negative results were analysed using 2 way frequency tables 
which can be used to relate 2 categorical variables. Analysis of frequency tables is 
based on hypothesis testing where the null hypothesis is that the 2 different variables 
are unrelated. The observed frequencies are compared with what would be expected if 
this hypothesis were true (Altman 1991). Calculations are based on the totals of the 
rows and columns of the tables as shown below 
Test 1 positive Test 1 negative Total 
Test 2 positive w x w+x 
Test 2 negative y z y+z 
Total w+y x+z N 
The Chi squared (x2) test is used to analyse these results using the formula: 
N(wz-xy)2 
z 
x= (w+x)(W+Y)(x+z)(Y+Z) 
A numerical value for x2 and a corresponding p value are generated, the p value 
suggesting whether there is an association between the variables. The smaller the p 
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value the lower the probability that the null hypothesis (that the variables are 
unrelated) is true. The value of p which is generally considered to be statistically 
significant is 0.05 which would correspond to 5% of observations falling outside the 
range which would suggest an association between the variables, a value which may 
be expected to occur by chance. If fewer than 5% of values are outside the range i. e. 
p<0.05 the null hypothesis may be rejected. 
If sample numbers are small the x2 test described above may introduce some 
bias into the calculation and a correction for this has been devised, this is known as 
the Yates' correction. In order to allow for correction where sample numbers are 
small it is advisable to perform the Yates' correction in all calculations as the effect of 
the correction will be very small if numbers are sufficiently large (Altman 1991). 
Where one or more of the expected values in a frequency table is less than 5 
the Yates correction is not appropriate and it is necessary to perform the Fisher's exact 
test, which is also based on the observed row and column totals of the 2 way table. 
x2 and Fisher's exact test were performed using the computer programme 
Epilnfo 6 version 6.04a developed by the Center's for disease control and prevention 
(CDC), U. S. A. 
Analysis of panel reactivities determined for the same sample by different 
methods requires testing of paired samples. The analysis of such data may be carried 
out by either parametric or non-parametric methods. For parametric methods the 
assumption that the data is normally distributed is made whereas non-parametric 
methods do not make assumptions about distribution. In analysis of paired data it is 
the differences between observations for the same samples which are of interest rather 
than differences between samples. The t-distribution is the principle parametric 
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method for analysing such data. This method compares the means of the values for 
the samples giving at value: 
t= 
sample mean - hypothesised mean 
standard error of sample mean 
for a paired t test the hypothesised mean is 0 as the hypothesis is that the 2 
observation are the same. Ap value can be derived from the t value, a significant p 
value (<0.05) will therefore reject the null hypothesis suggesting that the observations 
for the paired samples are significantly different. 
The parametric t test assumes that the distribution of the within sample 
differences is normal. If this assumption is not valid a non-parametric method should 
be used. The corresponding non-parametric method for analysis of paired samples is 
the Wilcoxon matched pairs signed rank sum test where the differences between 
paired observations are calculated and assigned a rank. 
If the distribution of the data is normal it is most appropriate to use a 
parametric method for statistical analysis, however if it is not clear whether the 
distribution is normal both parametric and non-parametric methods may be used. If 
the results of the 2 analyses are similar it is probable that the assumption of normal 
distribution is correct however if the results differ the non-parametric method will be 
the appropriate measure of significance (Altman 1991). The t distribution and the 
Wilcoxon test have been used for the comparison of panel reactivities using the 
statistical computer programme SPSS for Windows version 6.0. 
Correlation coefficients may be used to provide a measure of the degree of 
association between 2 variables, they do not give a measure of how closely the 
variables agree. A measurement of correlation is therefore not appropriate for testing 
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the agreement of results produced by 2 different methods (Altman 1991), it can 
however provide an indication of the ability to predict the value of one measurement 
from the known value of the other measurement. The Pearson correlation coefficients 
have been calculated in some of the comparisons of PR determination by different 
methods to indicate whether the results obtained using one method may be used to 
predict those obtained with another method. 
The analysis of levels of panel reactivity for groups of patients with failed 
grafts with different degrees of HLA match has been carried out by an analysis of 
variance. In this type of analysis the null hypothesis is that the mean and variance of 
different populations (different matching grades) will be the same. With ordered 
groups, such as those containing patients with increasing numbers of mismatches it is 
most appropriate to use a method which determines whether there is a trend across the 
groups rather than differences between each of the individual groups. The Kruskal- 
Wallis test is a non-parametric method for analysis of variance which can be used to 
assess trends (Altman 1991). The Kruskal-Wallis test was performed using the 
computer programme SPSS for Windows version 6.0. 
Analysis of graft survival has been performed using life tables and Kaplan- 
Meier survival curves. Actuarial survival curves have been generated using life 
tables. The null hypothesis in survival analysis is that the survival of different groups 
will be the same. Comparison of survival between groups has been performed using 
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the log rank test for Kaplan-Meier curves, which uses observed and expected 
incidences of failure during separate time intervals. This method is used for 
comparing 2 different groups, it is also possible to carry out an analysis for trend 
across 2 or more groups. The computer programme SPSS for Windows version 6.0 
has been used to perform these analyses for matching at HLA-DR and HLA-A, B, DR. 
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Figure 2.1 Gating of pooled EBV cells by FSC and SSC 
on the FACScan 
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#3: GI GE©21 \FL 1-H,. FL 1-He i soh t 
--- Arithmetic Histogram Statistics for 03: BIGE021 --- 
Selected Preferences: Arithmetic/Linear 
Parameter FLi-H FO-Height ungated 
M Left, Right Events % Peak Pi; Chl Mean Median SD CV % 
- ----------- -------- ------ ------ ------ ------- ------- ------ ------ 
@ 1.00,9646 10000 100.00 269 29.43 78.21 32.78 378.81 >100.0 
1 143,9646 705 7.05 37 143.30 612.46 245.82 1312.79 )100. E' 
#3: BIGE043\FLI-H\FL1-Height 
--- 4rithmetic Histogram titatistics for N3: BIGE943 --- 
Selected Preferences: Arithmetic/Linear 
Parameter FL1-H FL1-Height Ungated 
M Left, Right Events % Peak PkChl Mean Median SD Cu % 
- ----------- -------- ------ ------ ------ ------- ------- ------ ------ 
1,00,9646 10000 100.00 218 339.82 628.43 392.42 921.53 >100.0 
1 143,8353 9178 91.78 218 339.82 635.47 421.70 765.16 >100.0 
Figure 2.2 Histograms of antibody binding for negative and positive samples with 
analysis gate and statistics generated by LYSYS II 
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------------------------------------------ SAMPLE INFO ----------------------------------------- 
PROTOCOL as bes screen analysis LAST HIST 00006708. H02 
DATA RATE Unknown TOTAL COUNT 12,877 LIST FILE 00008708. LMD 
INSTRUMENT XL V33150 PROT FILE EE000023. PRO 
SAMPLE NAME NoRead 69/30 SAMPLE DATE: 03May94 
SAMPLE NUMBER: 00008708 SAMPLE TIME: 13: 24: 14 
COMMENTS 
------------------------------------------ STATISTICS -------------------------- ---------------- 
SINGLE PARAMETER STATISTICS 
...... Punk...... .............. X Channel ............... 
ID Pcnt Ar.. Position Height Moan SO Fu11CU HalfCU Min Max 
8 9.0 900 2.2 17 3.73 2.03 54.6 2.10 2.1 1015 
DUAL PARAMETER STATISTICS 
...... Peak....... .... X Channel.... .... Y Channel.... 
ID Pont Area Position Height Mean SD CU Mean SD CU 
A 77.7 10000 29,10 89 32.9 8.1 24.6 12.3 4.6 37.4 
B Low Channel = 2.1, High Channel = 1016 positive 
A sebeuvas amorphous 
Figure 2.3 Gating of pooled EBV cells by FS and SS, 
and FL 1 histogram on the EPICS-XL 
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CHAPTER 3 
DEVELOPMENT OF FLOW CYTOMETRIC SCREENING 
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Flow cytometric crossmatching is a standard technique used for crossmatching 
all sensitised potential transplant recipients against donor cells in this centre. The 
technique used is based on that described by Cook et al (1987). This technique is 
known to be more sensitive than the standard crossmatch. One reason for developing 
a flow cytometric based screening technique was so that a screening method of similar 
sensitivity to the final crossmatch method was available. Cytotoxic screening is time 
consuming and it takes several weeks to get a result if random cell panels are used. 
Using flow cytometry for analysis of antibody binding allows data on many thousands 
of individual cells to be collected in a matter of minutes. The possibility of using 
pooled cells in a flow cytometric based technique therefore seemed feasible. Pooled 
cells cannot practically be used in cytotoxicity where the relatively small number of 
cells analysed in each well of a Terasaki plate would not guarantee adequate 
representation of each cell in the pool so that reactions with only a single component 
of the pool would be detected. 
Pooled platelets were obtained from the Tissue Typing Laboratory at the 
Oxford Transplant Centre. The pool contained platelets from approximately 150 
donors. The pooled platelets were stored in suspension at 4°C until required. 
CLL cell lines were obtained from the Oxford Transplant Centre. The cells 
were supplied as individual aliquots which were counted and pooled in volumes such 
that each cell was represented in equal numbers within the pool. The pooled cells 
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were washed twice by centrifuging at 400g for 5 minutes in FACS diluent. The 
pooled cells were resuspended in FACS diluent at a concentration of 5x106/ml. 
EBV cell lines were grown and pooled as described in section 2.4. 
The single colour flow cytometric antibody binding assay was performed as 
described in section 2.5.4. Analysis of the antibody binding was performed using the 
Becton Dickinson FACScan. 
Cytotoxic screening against peripheral blood lymphocytes and CLL cells was 
performed as described in section 2.3.4. 
Platelets were selected as the initial target for developing a flow cytometric 
screening assay because they express HLA class I but not class II antigens and would 
therefore be an appropriate target for comparison with CDC screening against 
peripheral blood T cells. An initial series of four screening runs was carried out. A 
total of 38 test sera were screened in this first series (platelet series 1), 13 of which 
were repeat tested. The sera were selected on the basis of known antibody specificity 
as determined by CDC screening with a small number of known negative sera 
included. 
A subsequent series (platelet series 2) was carried out using 60 test sera. The 
serum samples were not pre-selected but were 30 consecutive patient samples 
received in each of the Tissue Typing Laboratories at Guy's Hospital and the Oxford 
Transplant Centre. 
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Twenty gl of serum was added to 30µl of pooled platelets to give a cell/serum 
ratio of 3: 2 in the antibody binding assay, the same ratio used for the flow crossmatch. 
Thirteen sera were rescreened using the same platelet pool as above and in 
addition sera were also tested at a dilution of 1: 4 by adding l0µl of serum to 30µl 
platelets. 
A significant correlation was found between cytotoxicity and platelet 
screening by flow cytometry for the sera tested (p=0.0078, Table 3.1, p107). There 
were however 9 samples with HLA specific antibodies detected by CDC screening 
which were negative by flow cytometry showing a false negative result in 31 % of 
CDC positive cases. Analysis of the platelet screening results of sera known to 
contain HLA A2 specific antibody indicated that the pooled platelets did not produce 
consistent results. Table 3.2 (p 108) shows the results of 8 of these sera. Serum 1 was 
clearly negative by platelet screening whilst the other 7 sera were positive although 
serum 4 showed antibody binding only just above background levels. Repeat testing 
of the sera at further dilutions demonstrated the inconsistencies of the technique. 
Serum 6 which showed the highest level of antibody binding at a dilution of 2: 5 was 
negative at dilutions of 1: 4 and 1: 8 whereas serum 3 showed an increase in the level 
of antibody binding at 1: 4 compared to 2: 5. 
As the flow cytometric analysis of pooled platelets did show a significant 
correlation with CDC screening a further series of sera were screened. However as 
there were inconsistencies in the platelet results it was decided to use CLL cells as an 
additional target and compare the results of CLL pools and platelet pools with 
cytotoxic screening against CLLs and PBLs respectively. The use of CLL pools 
99 
would have the advantage of providing a suitable target for the detection of HLA class 
II specific antibodies in addition to class I specific antibodies. 
Sixty sera were tested at dilutions of 1: 4 and 1: 8 against the platelet pool as 
described in 3.3.1. (The same samples were tested with CLL pools in CLL series 1). 
The platelet screening did not correlate sufficiently well with the results of 
CDC screening against T lymphocytes in this series of samples (Table 3.3, p109). 
There were 12 and 11 false negative results with platelets at 1: 4 and 1: 8 serum 
dilutions respectively, although at the 1: 8 dilution there was a statistically significant 
correlation for detection. Figure 3.1 (p114) shows the comparison of panel 
reactivities detected by 2 methods with percentage antibody binding being used as a 
measure of PR for the flow screening. Platelet screening did not give a PR of greater 
than 40% in any of the samples tested whilst CDC screening showed 9 samples with 
PRs of over 40%. In view of the high number of false negative reactions and poor 
correlation for PR it was concluded that platelet screening was not a suitable method 
for the detection of HLA class I specific antibodies. 
A total of 60 test sera were screened. Three groups of 20 sera each were 
screened with one of 3 CLL pools. Pools were made by combining equal volumes of 
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CLL cells at a concentration of 5x106/ml. Figure 3.2 (p115) details the CLL lines 
used. Pool 1 contained 10 CLLs, pool 2 contained 8 CLLs and pool 3 contained 11 
CLLs. 
Sera were tested at 2 dilutions. For a dilution of 1: 4 1 0µl serum was 
dispensed into each tube and 30µl pooled CLL cells added. For a working dilution of 
1: 8 5µl of serum was dispensed into each tube and 35µl CLL cells added. 
The correlation between flow cytometric screening of CLL pools and 
cytotoxic CLL screening results was highly significant at both the serum dilutions 
tested (Table 3.4, pl 10). At both dilutions there was only 1 sample which was 
positive by CDC screening which was not detected by flow cytometry. At 1: 4 there 
were 3 samples which were flow positive, CDC negative whereas at 1: 8 six samples 
were flow positive, CDC negative. 
The panel reactivities of each sample determined by the two different method 
were compared and the Pearson correlation coefficient calculated. These differed 
slightly at the 2 dilutions tested with overall coefficients of rß. 882 for sera tested at 
1: 4 and r=0.916 for sera tested at 1: 8. The correlation coefficients for each individual 
pool are shown below: 
Pool 1 (n=10) 1: 4 r=0.954 1: 8 r=0.932 
Pool 2 (n=8) 1: 4 r=0.893 1: 8 r=0.896 
Pool3(n=11) 1: 4r=0.921 1: 8r=0.942 
The strong correlation between CDC and flow cytometric screening for 
estimation of panel reactivity with CLL cells was better than might have been 
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expected. The PR for the pools was based on antibody binding to 8,10 or 11 cells 
whereas PR estimated by CDC screening was the result of testing against 30 cells. 
The smaller pools would not contain sufficient cells to cover all the HLA antigens 
represented in the CDC panel. The r values of between 0.893 and 0.954 may 
therefore indicate that the antibodies present in the serum samples tested were directed 
against the most commonly represented antigens in both the pools and the panel but 
that sera containing antibodies specific to a single or small number of less commonly 
represented antigens may not have been present in the randomly selected samples. In 
view of this possibility the serum samples to be tested in the next series of CLL 
screening were selected to contain a wide variety of panel reactivities and antibody 
specificities 
Thirty sera were selected based on previous CDC screening results to cover a 
range of panel reactivity levels and antibody specificities. The sera were tested 
against 2 pools of CLLs comprising a total of 18 CLL cells. Figure 3.3 (p116) gives 
the HLA types of the cells in each of the 2 pools. Sera were tested at a working 
dilution of 1: 5. Ten µl of serum was dispensed into each tube and 40µl of pooled CLL 
cells added. 
There was a significant correlation between flow screening of the CLL pools 
and the CDC screening against CLL cells (Table 3.5, p 111). There were 14 samples 
which were positive by both methods, 9 of these were shown to contain HLA class I 
102 
specific antibodies by CDC screening of PBLs and CLLs and 5 contained class II 
specific antibodies only as was demonstrated by negative results with CDC screening 
of PBLs. 
The use of 2 pools comprising 18 CLL cells in total did not produce a higher 
correlation found for panel reactivities, than those found with the smaller pools, with a 
correlation coefficient of 0.887 being found when the mean PR for the 2 pools was 
compared with the CDC PR. Figure 3.4 (p 117) shows the PRs determined by flow 
and CDC screening for each sample. The pooled screening did detect antibodies with 
CDC panel reactivities of 10 and 13 % with pool PRs of 21 and 44 % respectively 
indicating that the pools contain sufficient cells to detect even low PR antibodies 
detected by CDC. There was a single sample which was CDC positive with a PR of 
26% which was flow negative, this samples was negative with PBLs suggesting an 
HLA class II specific antibody was present. There was insufficient sera to test this 
sample with DTT so it is possible that the antibody detected by CDC screening was an 
IgM antibody. Four samples were found to be flow positive but were CDC negative, 
this may be due to the greater sensitivity of the flow technique or it may be possible 
that the antibodies detected were not HLA specific. 
The overall results of the CLL screening series showed a significant 
correlation between CDC and flow cytometric screening of CLL cells with similar 
panel reactivities being determined by the 2 methods despite the smaller size of the 
panel used for flow screening. Both HLA class I and class II specific antibodies were 
detected by this method. The method was therefore adopted as a suitable technique for 
the rapid detection of HLA class I and class II specific antibodies. 
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Additional flow cytometric testing of pooled CLL cells was subsequently 
performed at the Oxford Transplant Centre. The results of screening serial dilutions of 
sera confirmed the greater sensitivity of the flow method compared with CDC 
screening (Sutton et al 1995). 
CLL cells had been shown to be a suitable target for flow cytometric screening 
of pooled cells. However for the envisioned high volume, routine use of the screening 
method CLLs would not be available in sufficient quantities. It was therefore decided 
to assess the suitability of cell lines which could be maintained in culture to produce 
large quantities of cells as required. EBV transformed B lymphoblastoid cell lines 
were chosen as a potential target as they were well characterised with HLA class I and 
class II types confirmed by biochemical and/or DNA typing methods and were 
available from a number of sources. In order to validate the use of EBV cell lines for 
screening using the methods devised for CLL pools was performed. 
A first screening run using a pool of 5 EBV cells (Figure 3.5, p 118) was 
carried out using 21 sera which were selected on the basis of antibody specificity 
determined by cytotoxic screening with 19 of 21 containing HLA specific antibody. 
The technique was identical to that used in the second series CLL screen with a serum 
cell ratio of 1: 4 being used. 
A second screening run using a pool of 10 EBV cells (Figure 3.6, p119). All 
the serum samples allocated to a plate for cytotoxic screening were screened by flow 
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cytometry immediately following pouring of the screening plate. The method used 
was as for the second series CLLs with a serum cell ratio of 1: 4. Antibody binding 
was analysed by single colour flow cytometry using the FACScan. The results were 
determined and compared with the results of the cytotoxic screen when the screening 
plate was complete. Forty seven random cells were used for the cytotoxic screening. 
The results of the first EBV screen against a pool of 5 cells was as detailed 
below. 
EBV Screen pos, antigen present in pool 9 
EBV Screen pos, antigen not present 3 
EBV screen neg, antigen not present 5 
EBV Screen neg' antigen present 2 
EBV Screen neg, cytotoxic neg 2 
2 sera were EBV neg despite the antigen to which they had specific antibody 
being expressed by cells in the pool. Both were HLA Al specific antibodies. Three 
other Al antibodies were detected in this screen. Three sera were positive with the 
EBV pool although CDC screening results had shown specificities for HLA antigens 
not represented in the pool. This suggests that additional antibody specificities were 
detected. These could be HLA class II specific antibodies or additional class I 
specificities detected by the more sensitive flow cytometric technique. The correlation 
between the 2 methods for detection of antibody is significant (p=0.024 table 3.6, 
pl 12) despite the small pool size and differences in target cells with respect to HLA 
antigen expression. 
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The results of the second series EBV screening are shown in table 3.7a 
(p113). Eight serum samples were CDC positive but negative by flow screening with 
the EBV pool. Five of these samples were subsequently shown to be CDC positive 
due to the presence of IgM antibodies by DTT screening. Therefore the results were 
reanalysed with the 5 IgM samples excluded from the analysis (Table 3.7b, p113). Of 
the 3 remaining samples which were EBV negative 2 had specificity for HLA A2, 
although one of these was weakly positive with only 10 of 19 A2 expressing cells in 
the CDC panel. Two EBV cell lines in the pool were A2 positive and four other 
samples with antibodies specific for HLA A2 were detected by the EBV screening 
showing that the pool was able to detect A2 specific antibodies. The reason for the 
failure in 2 samples is not clear. The remaining `false negative' sample gave weak 
reactions on CDC screening with no discernible specificity. No further samples were 
obtained from this patient for CDC screening and it was not possible to determine 
whether the reactivity shown by the CDC screen was due to HLA specific antibody. 
The correlation between the 2 methods was significant with ap value similar to that 
for the CLL screening indicating that EBV cell lines were an appropriate target for 
flow cytometric screening. 
The results of the CLL and EBV pooled screening series indicated that flow 
cytometric analysis of antibody binding to pooled cells was a reliable method for the 
detection of IgG HLA specific antibodies. Flow cytometric screening of pooled EBV 
cell lines (Flowscreen) was therefore adopted as the screening method for detection of 
HLA class I and class II specific antibodies and was the principle method used in the 
study of antibody production in transplant patients 
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Platelet Pos Platelet Neg 
Cytotoxic class I pos 20 9 
Cytotoxic class I neg 1 8 
x2 = 7.11 p=0.0078 
Table 3.1 Comparison of flow cytometric screening with pooled platelets 
and cytotoxic screening with T lymphocytes 
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2: 5 1: 4 1: 8 
1 5.74 NT NT 
2 38.09 25.8 36.07 
3 31.05 40.32 22.16 
4 18.67 8.17 3.06 
5 26.66 NT NT 
6 43.98 15.77 14.03 
7 20.88 15.65 10.60 
8 36.04 NT NT 
Table 3.2 Platelet PR for HLA A2 specific sera tested at 3 dilutions 
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Platelet flow + Platelet flow - 
Cytotoxic PBL + 6 12 
Cytotoxic PBL - 8 34 
a. 
Fisher's exact p=0.192 
Platelet flow + Platelet flow - 
Cytotoxic PBL + 7 11 
Cytotoxic PBL - 6 36 
b. 
Fisher's exact p=0.041 
Table 3.3 Comparison of flow screening of platelet pools with cytotoxic screen 
of PBLs. Serum at dilutions of a) 1: 4, b) 1: 8 
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Flow + Flow - 
Cyto + 20 1 
Cyto - 3 36 
a. 
b. 
x2 = 40.63 p<0.0001 
Pearson correlation = 0.882 
Flow + Flow - 
Cyto + 20 1 
Cyto - 6 33 
x2=32.27 p<0.0001 
Pearson correlation = 0.916 
Table 3.4 Comparison of cytotoxic and flow screening methods for 
combined CLL pools at serum dilutions a) 1: 4, b)1: 8 
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Flow + Flow - 
Cytotoxic + 14 1 
Cytotoxic - 4 11 
2 = 11.25 p= 0.00 12 
Pearson Correlation Coefficient r=0.887 
Table 3.5 Comparison of flow screening of 30 sera with 2 pools of CLL, (mean 
of pools) 
III 
Flow pos Flow neg 
Cytotoxic + 9 2 
Cytotoxic - 3 7 
Fishers exact p=0.024 
Table 3.6 Comparison of PBL, CDC and Flow Cytometric screening of a pool 
of 5 EBV cell lines 
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EBV Flow pos EBV Flow neg 
Cytotoxic pos 19 8 
Cytotoxic neg 1 8 
a. 
Fisher's exact p=0.0028 
EBV Flow pos EBV flow neg 
Cytotoxic pos 19 3 
Cytotoxic neg 1 8 
b. 
Fisher's exact p=0.00017 
Table 3.7 Comparison of flow screening of pooled EBV cell lines with 
cytotoxic screening a) including IgM containing sera b) excluding IgM 
containing sera 
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A1,28 B8,44 Cw5,7 DR4,8 DQ7 
A2 B7,62 Cw3,7 DR2,4 DQ6,8 
A3,11 B7,35 Cw4 DR7,8 DQ2,4 
A1,3 B8,18 Cw- DR3,16 DQ2,5 
A2 B 18,40 Cw3 DR4,13 DQ6,7 
A1,9 B8,18 Cw- DR3,11 DQ2,7 
A2,29 B8,44 Cw7 DR3,7 DQ2 
A2,24 B7,62 Cw3 DR9,13 DQ6 
A3,28 B51 Cw4 DR11,14 DQ5,7 
A2 B44 Cw5 DR4 DQ7 
A2,24 B35,38 Cw4 DR1,13 DQ5 
A2,29 B44,60 Cw3 DR7,13 DQ2,6 
A2,28 B60 Cw3,8 DR12,13 DQ7 
A3,26 B5 Cw- DR4,12 DQ7 
A3,31 B7,52 Cw7 DR2,14 DQ1 
A1,3 B7,37 Cw6,7 DR4,10 DQ3 
A1,25 B17,18 Cw6 DR1,4 DQ5,8 
A2,24 B51,18 Cw2 DR7,11 DQ2,3 
A3,29 B7,44 Cw- DR2 DQ 1 
A2,3 B35,44 Cw5 DRI, 4 DQI, 3 
Figure 3.2 HLA types of CLL Cells used for CLL Series 1 
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A2 B13,15 Cw3,6 DR2,4 DQ6,8 
A3,11 B7,35 Cw4 DR7,8 DQ2,4 
A1,9 B8,18 Cw- DR3,11 DQ2,7 
A1,28 B8,44 Cw5 DR4,8 DQ7 
A23,29 B44,13 Cw- DR7 DQ2 
A1,3 B7,37 Cw6 DR4,10 DQ- 
A2,24 B18,51 Cw2 DR7,11 DQ2,3 
A2,32 B62 Cw3 DR1,11 DQ5,7 
A1,2 B8,44 Cw5 DR2,12 DQ1,3 
A2,24 B7,62 Cw3 DR9,13 DQ6 
A3,26 B5 Cw- DR4,12 DQ3,7 
A2 B51,62 Cw9 DR3,9 DQ- 
A2,24 B7,55 Cw9 DR14,15 DQI 
A3,31 B7,52 Cw7 DR1 DQ- 
A2 B8,39 Cw- DR3,13 DQ2,6 
A2,28 B13,60 Cw3,8 DR12,13 DQ7 
A2,24 B35,38 Cw- DR1,13 DQ5 
Figure 3.3 HLA types of CLL Cells used for CLL series 2 
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Al,! B8,8 Cw7,7 DR3,3 DQ2 
A30,68 B42,42 Cw2,2 DR3,3 DQ4 
A31,31 B62,62 Cwl, l DR8,8 DQ4 
A29,29 B61,61 Cw2,2 DR11,11 DQ7 
A28,28 B53,53 Cw4,4 DR15,15 DQ6 
Figure 3.5 HLA types of EBV cells in Pool 1 
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A33,33 B14,14 Cw8,8 DR1,1 DQ- 
A1,1 B8,8 Cw7,7 DR3,3 DQ2 
A30,68 B42,42 Cw2,2 DR3,3 DQ4 
A2,2 B44,44 Cw5,5 DR4,4 DQ3 
A2,2 B57,57 Cw6,6 DR7,7 DQ2 
A31,31 B62,62 Cwl, 1 DR8,8 DQ4 
A24,24 B51,63 Cw-, - DR11,11 DQ7 
A29,29 B61,61 Cw2,2 DR11,11 DQ7 
A11,11 B35,35 Cw4,4 DR6,6 DQI 
A28,28 B53,53 Cw4,4 DR15,15 DQ6 
Figure 3.6 HLA types of EBV cells in Pool 2 
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CHAPTER 4 
PRA-STAT SCREENING: COMPARISON WITH 
LYMPHOCYTOTOXICITY AND FLOW CYTOMETRY 
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PRA-STAT is a commercially produced ELISA based method for the 
detection of HLA specific antibodies as described in section 2.6. It was marketed as a 
method which detected HLA class I specific antibodies only based on the premise that 
a class I specific monoclonal antibody was used to capture solubilised antigen and 
attach it to the bottom of the wells in 96 well plates. The method is designed to use an 
IgG specific conjugate and therefore only IgG HLA class I specific antibodies should 
be detected. It was therefore decided that the data obtained from PRA-STAT 
screening would be useful in addition to cytotoxic and flow cytometric screening 
techniques and help in the determination of antibody specificity. Cytotoxic screening 
detects both IgG and IgM antibodies and some non-HLA specific antibodies. 
Flowscreen detects IgG HLA class I and class II specific antibodies. If PRA-STAT 
could be used to conclusively detect IgG HLA class I specific antibodies comparison 
with Flowscreen results should indicate when Flowscreen was detecting IgG class II 
specific antibody in the absence of class I specific antibody. 
An initial assessment of PRA-STAT was carried out using sera from patients with 
well defined HLA class I specific antibodies detected by cytotoxicity along with some 
consistently negative sera and sera know to contain IgM antibodies. A total of 32 sera 
were tested. 
For initial comparison of flow cytometric and PRA-STAT screening methods 
consecutive serum samples from 16 patients receiving renal allografts were analysed. 
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STAT results. Treating the sera with DTT prior to adding to the PRA-STAT plates 
did not alter the results with the PRs remaining exactly the same. 
In four samples the same major specificity was found by both methods but 
extra class I specificities were shown by cytotoxic screening. Eleven samples showed 
detection of the same major specificity by both methods but higher panel reactivities 
were detected by PRA-STAT. In these cases the extra reactivity did not correspond 
with clearly defined class I specificities with the positive reaction, often making no 
apparent sense. 
Although the results of this initial assessment were disappointing in that the 
specificity analysis did not appear to correspond with the results of the well 
established cytotoxic screening it was decided to continue with a comparative analysis 
of PRA-STAT and Flowscreen. 
The results of screening the sequential serum samples from 16 patients 
receiving renal transplants showed a significant correlation between the two screening 
methods (p<0.001). There were no examples of PRA-STAT positive, Flowscreen 
negative samples and only 6/121 were Flowscreen positive PRA-STAT negative 
(Table 4.3, p130). The panel reactivities for the 24 positive samples were similar with 
changes in panel reactivity being clearly shown by both methods. Figures 4.1 and 4.2 
(p133 & 134) show an increase in panel reactivity following transplantation in 2 
patients, these changes accompanied an irreversible rejection episodes in one of these 
patients. Figure 4.3 (p 135) shows a patient with no antibody production being 
detected by either method. Only the samples from one of the 16 patients studied did 
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not produce similar results by both methods (Fig 4.4, p136). This patient was know to 
have a strong IgM autoantibody prior to transplantation. It is also possible that the 
antibody detected by Flowscreen in this patient was not HLA specific. 
The similarity of results of the PRA-STAT and Flowscreen against B cell lines 
suggested that the same antibodies were detected by both methods. Flowscreen 
detects both HLA class I and class II antibodies. After showing the results of the 
comparative study to SangStat representatives we were advised that the method was 
able to detect HLA class II specific antibodies and not class I only as previously 
stated. An updated list of panel HLA types was provided by SangStat giving the HLA 
A, B, DR and DQ types (Table 4.4, p131). This information was also provided as an 
update to the SOFT-STAT software. The results of genotyping the PRA-STAT cell 
lines by a PCR-SSP method at the Oxford Transplant Centre (Bunce et al 1995) were 
used for comparison, the HLA A, B, C, DRB 1,3,4,5 and DQB 1 types were given (table 
4.5, p132). 
The PRA-STAT results were reanalysed by the updated SOFTSTAT 
programme and by manual analysis using the genotyping data for HLA class I and 
class II specific antibodies. In the initial assessment of the PRA-STAT technique 11 
samples gave extra reactions by PRA-STAT. In seven samples the extra reactions 
were shown to be due to HLA class II specific antibodies. In five of these seven cases 
the antibody was found to be specific for class II mismatched antigens on renal 
allografts (both HLA DR and DQ specific antibodies were detected), in the remaining 
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EBV Flow pos EBV Flow neg 
Cytotoxic pos 19 8 
Cytotoxic neg 1 8 
a. 
Fisher's exact p=0.0028 
EBV Flow pos EBV flow neg 
Cytotoxic pos 19 3 
Cytotoxic neg 1 8 
b. 
Fisher's exact p=0.00017 
Table 3.7 Comparison of flow screening of pooled EBV cell lines with 
cytotoxic screening a) including IgM containing sera b) excluding IgM 
containing sera 
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2 cases the class II types of the failed transplants were not known as the transplants 
were performed before class II typing was routinely available. 
The results of the specificity analysis showed that 11 of the 24 positive sera in 
the comparative study had antibodies specific to HLA class I antigens only. Four 
samples had class II specific antibodies and 4 contained both class I& II specific 
antibodies. In five cases a panel reactivity of over 95% prevented accurate specificity 
analysis. 
Figures 4.5 and 4.6 (p137 & 138) show the results analysing a sample using the class I 
panel or the class I+ class II panel. The antibody specificity is demonstrated by the 
marking of antigens. The class I antibody specificity had been previously determined 
by cytotoxic testing to be A2 This corresponded to a mismatched antigen present on a 
failed renal allograft. It can be seen from the class I analysis that there are 19 extra 
positive reactions not due to the A2 specific antibody. However when the class I+ II 
panel is used it is clear that the extra reactions are due to the class II specific antibody. 
Only 3 of 33 positive reactions could not be accounted for by the A2, DR2, DQ1 
specificity. 
A comparison of the HLA class I types provided with the kits and the 
genotypes show a number of discrepancies in wells nos. 14,21,22,29,31,33 and 38 
(tables 4.4 and 4.5, p131 & 132). In 2 cases these discrepancies show that an HLA B5 
antigen detected by genotyping was not detected or was misassigned by the original 
phenotyping (wells 21 and 38). This is confirmed by analysis of samples from a 
patient who received a renal allograft mismatched for HLA B51 who was screened as 
part of the comparative study (Figure 4.7, p139). Of the 8 positive reactions 5 would 
be shown to contain HLA B5 antigens using the SOFT-STAT analysis whereas 7 of 
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the 8 were B5 positive when the genotyping results were used as is shown by the 
handwritten amendments to the results report. One B51 containing well was found to 
be negative but this had the highest delta value of all the negative results and was only 
just below the cutoff derived by SOFT-STAT. 
This result strongly suggests that the genotypes be used as the definitive HLA 
type for the panel and the results of subsequent PRA-STAT assays have therefore all 
been manually checked using this data. 
PRA-STAT results had been shown to be consistently reproducible across 
individual plates and between plates within the same lot in the original study by 
Buelow et al (1995). In order to confirm this the ODs for each of the 46 test wells 
across the 4 plates were plotted for the sequential samples screened in the comparative 
study. Figure 4.8 shows the ODs for a patient where no antibody production was 
detected. The reactivity of each sample with the individual wells is clearly very 
similar for all 8 samples. Figure 4.9 (p141) shows the plot of ODs for 2 samples from 
the same patient tested on different plates and again the reproducibility of reactivity is 
clear. 
OD plots were drawn for all 16 patients in the comparative study. In patients 
where no antibody production was demonstrated the plots were all similar to that 
shown in figure 4.8 (p140). In these patients the pre-transplant sample consistently 
showed the highest OD values with all the post-transplant samples mirroring the pre- 
transplant samples at slightly lower ODs. This corresponds to a slight decrease in the 
background binding seen with Flowscreen (figure 4.3, p135). When antibody is 
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detected the ODs rise above the pre-transplant level in both positive and negative 
wells as shown in figure 4.10 (p142). 
Having detected the trend for ODs to fall below the pre-transplant level careful 
analysis of the ODs in patients where antibody production occurred indicated the 
possibility of using OD plots to provide early detection of antibody production. 
Figure 4.11 (p143) shows the pre-transplant and 3 post-transplant samples from one 
patient. As in all cases the day 2 sample falls below the pre-transplant level. 
However in sample 7B (the latter of 2 samples drawn several hours apart on day 7) 
several wells show a rise in OD above the baseline and there is a change in the overall 
pattern of reactivity. None of these reactions reached the positive cutoff value 
however and a PR of 0% was recorded. Figure 4.12 (pp 144) shows the OD plot for 
these samples together with those of the subsequent sample. The difference in scale 
on the y axis recording the OD values should be noted. The OD values have risen 
significantly for all 46 wells with a panel reactivity of 98% on day 9, just 2 days after 
the first indication of a rise above the base level. Some of the strongest reactions in 
the day 9 samples are found in the wells where the small rise in OD was first detected 
and correspond to a specificity for a mismatched antigen 
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CDC positive CDC negative 
PRA-STAT positive 26 0 
PRA-STAT negative 2 6 
Fisher's exact p<0.0001 
Table 4.1 Comparison of lymphocytotoxicity and PRA-STAT for the 
detection of HLA class I specific antibodies 
128 
CDC CDC + DTT PRA-STAT Flowscreen 
Sample 1 66% 37% (Al) 24% 50% 
Sample 2 64% (A1,36,23,24) 11% 
Sample 3 26% (A1,36) 7% 
Table 4.2 Detection of IgG HLA Al specific antibody in the presence of 
IgM autoantibody. Comparison of cytotoxic, PRA-STAT and 
Flowscreen methods. 
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PRA-STAT Positive PRA-STAT Negative 
Flowscreen positive 24 6 
Flowscreen negative 0 91 
x2 = 85.85 p<0.001 
Table 4.3 Comparison of PRA-STAT and Flowscreen for the detection 
of HLA specific antibody in renal transplant recipients. 
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well no. A A B B DR DR DQ DQ 
3 1 52 15 6 
4 30 18 17 2 
5 24 55 61 15 13 6 
6 23 14 4 9 
7 32 38 11 7 
8 29 61 11 7 
9 1 41 11 7 
10 24 60 9 9 
11 31 60 4 8 
12 31 62 8 4 
13 1 57 7 2 9 
14 24 14 1 5 
15 1 61 14 5 
16 24 26 61 51 9 9 
17 33 68 58 38 15 17 2 6 
18 11 32 39 62 1 8 4 5 
19 3 23 50 55 3 14 2 5 
20 11 33 54 51 15 13 5 6 
21 3 35 27 1 5 
22 2 29 41 13 7 
23 2 54 62 4 4 
24 2 33 7 14 4 7 2 8 
25 2 68 8 50 17 7 2 
26 3 29 7 44 15 7 2 6 
27 26 44 39 11 14 5 7 
28 33 44 58 7 13 8 2 
29 31 32 13 51 15 7 2 6 
30 3 11 18 52 11 17 2 7 
31 1 23 49 35 17 7 2 5 
32 2 34 8 41 4 17 2 8 
33 1 30 8 63 17 13 6 2 
34 2 63 52 4 15 6 8 
35 2 26 49 57 1 7 5 9 
36 24 44 27 4 15 5 7 
37 2 25 18 45 4 16 4 5 
38 2 24 27 4 4 
39 25 11 7 37 11 15 6 7 
40 1 2 39 58 4 14 5 8 
41 25 30 13 55 1 15 5 6 
42 2 13 60 15 14 5 6 
43 29 32 45 35 4 11 7 8 
44 2 3 50 18 3 2 
45 24 69 44 49 1 11 5 7 
46 1 2 8 27 1 17 2 5 
47 2 23 49 55 11 14 5 7 
48 24 57 7 9 
Table 4.4 HLA-A, B, DR, DQ phenotypes of PRA-STAT panel 
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well no. A A B B Bw C C DRBI DRB1 DRB3,4,5 DQB1 DQB1 
3 1 52 4 12 15 51 601 
4 30 18 6 5 17 52 2 
5 24 55 61 6 3 9 15 13 51,52 6 
6 23 14 6 8 4 53 9 
7 32 38 4 12 11 52 7 
8 29 61 6 2 11 52 7 
9 1 41 6 17 11 52 7 
10 24 60 6 3 9 53 9 
11 31 60 6 3 4 53 8 
12 31 62 6 1 3 8 4 
13 1 57 4 6 7 53 2 9 
14 24 33 14 6 2 8 1 5 
15 1 61 6 15 14 52 5 
16 24 26 61 51 4,6 8 14 9 53 9 
17 33 68 58 38 4 10 12 15 17 51,52 2 602 
18 11 32 39 62 6 1 15 1 8 4 5 
19 3 23 50 55 6 3 6 3 14 52 2 5 
20 11 33 54 51 4,6 1 10 15 13 51,52 5 603 
21 3 35 51 4,6 4 15 1 5 
22 2 41 6 17 13 52 7 
23 2 54 62 6 1 3 4 53 4 
24 2 33 7 14 6 8 15 4 7 53 2 8 
25 2 68 8 50 6 6 7 17 7 52,53 2 
26 3 29 7 44 4,6 7 16 15 7 51,53 2 602 
27 26 44 39 4,6 5 12 11 14 52 5 7 
28 33 44 58 4 3 7 7 13 52,53 604-9 2 
29 30 32 13 51 4 7 6 15 7 52,53 2 602 
30 3 11 18 52 4,6 12 12 11 17 52 2 7 
31 1 23 49 53 4 4 7 17 7 52,53 2 5 
32 2 34 8 41 6 7 17 4 17 52,53 2 8 
33 1 31 8 63 4,6 7 17 13 52 604-9 2 
34 2 63 52 4 7 12 4 15 51,53 602 8 
35 2 26 49 57 4 6 7 1 7 5 9 
36 24 44 27 4 1 5 4 15 51,53 5 7 
37 2 25 18 45 6 6 12 4 16 51,53 4 5 
38 2 24 27 52 4 12 15 4 53 4 
39 25 11 7 37 4,6 6 7 11 15 51,52 602 7 
40 1 2 39 58 4,6 10 12 4 14 52,53 5 8 
41 25 30 13 55 4,6 6 3 1 15 51 5 601/2 
42 2 13 60 4,6 3 6 15 14 51,52 5 602 
43 29 32 45 35 4,6 4 6 4 11 52,53 7 8 
44 2 3 50 18 6 5 6 3 52 2 
45 24 69 44 49 4 4 6 1 11 52 5 7 
46 1 2 8 27 4,6 1 7 1 17 52 2 5 
47 2 23 49 55 4,6 3 7 11 14 52 5 7 
48 24 57 4 6 7 9 
Table 4.5 HLA dass I class II genotypes of PRA-STAT panel 
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Date: 26.0997 Page: 1 
Sample Report Time: 101131 
Date. 31107/96 Run ID 31/07196-1 Lot 8580 
Patient ID X134 Name. 
Sample ID: DE3A Draw Date. 17106194 Tech ANDREA Row E 
Test Parameters Mean PR 1.651 
Lot Calc: BasicBw46 X Ratio Factor. 0.35 
n Invalid Sample 
Dilution: 1: 101 Analysis: Fishers = Cutoff Used: 0.577 
Q Invalid Run 
PRA: 72% 
Interpretation: 
Row A R ow B Row C Row D Row E Row F Row G Row H 
Control OD's: 1 861 1. 593 1.656 1 550 1 . 
556 1.691 0 362 0 384 
Statistics 
Aat 9 TP PP TN TN P A At f TP TP TN TN P A Ant 
I TP FP TN TN PA 
Res ult Su mmary by Delta 
well OD Delta Bis A B Broad Well OD Dolt. 8.. A B Broad 
'El 
32 3.999 3.865 Fs 'u 8 41 A12 14 0.8'3 03 
29 2.131 2.022 5; 0_3, E5 31 0.854 G. . -1 1 4? A3,8-1 
35 1.895 1.764 F 4. 4 S? A10,821,91ý 36 0.836 0.705 P. s -4 44 A9,812 
42 1.731 1.602 25 _. 
62 B40 40 0.828 0.697 P03 0 "3 .9 816,817 
23 1.687 1.5`. 6 FD `ý 62 62J, E: 44 0.795 0.664 POS ... `. 0 B21 
46 1.608 1.47 .0 _ 
26 0.789 0.658 P_ 74 013,212 
37 1.475 1.344 42 A!,., 112 11 0. -50 0.619 F.., .. 013,94 
41 1.457 1.32§ `. 5 A1-., Ai?, 822 19 0.661 0.530 003 3 23 03 55 A9,821,822 
22 1.33' .. 26F " '- 54 019,90,922 
27 0.612 C. 481 NEG 26 39 44 012,2: 6, e_2 
34 1.379 1.249 42 63 BE_, 815 30 3.580 0.449 NEG 3 11 18 52 85 
1.335 1.224 C YLýJ7 - 
41 Al? 7 0.560 0.429 NEG 32 38 019,916 
11 1.234 1.109 =S -2 
38 58 A19, E16, B1" 45 0.555 0.424 NEG 24 28 44 43 A9,812,821 
24 1.200 1.06? 4-44 
D- ' 14 A19 13 0.538 0.407 NEG 1 5- 81" 
4 1.127 0.9? ' 18 A19 48 0.479 0.348 NEG 24 57 A9, B17 
39 1.091 5.962 7 37 010 6 0.414 0.283 NEG 23 14 A? 
_2 1.064 
0.933 5.1 62 019, E15 10 0.411 0.280 NEG 24 65 A?, 842 
3 1.037 0.906 005 1 52 85 
8 0.354 0.223 NEG 29 61 019,840 
21 1.035 0.904 525 3 27 35 16 0.314 0.183 NEG 24 26 51 61 A?, . 010,29,943 
15 0.982 0.851 = 61 B42 43 0.250 0.119 NEG 29 32 35 45 019,812 
28 0.974 3.84 40 58 013, E12,817 9 0.206 2.075 NEG 1 41 
38 0.967 0.81- .ýD 
27 A9 1 1.556 -1.000 
18 0.965 3.854 ". 39 62 019,816,815 2 0.131 -1.000 
Figure 4.5 SOFT-STAT report showing analysis 
using class I panel only 
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Sample Report 
Date: s097 Page: 1 
Time: 10: 10: 36 
Date: 31107196 Run ID 31107196-1 Lot: 8580 
Patient ID: X134 Name: 
Sample ID: DE3A Draw Date: 17106194 Tech: ANDREA Row: E 
est Parameters Mean PR 1.661 
Lot Calc. Class 1+11 X Ratio Factor 0.36 Invalid Sample 
Dilution: 1: 101 Analysis: Fishers = Cutoff Used: 0.677 
Q Invalid Run 
PRA: 72% 
Interpretation: 
Row A Row B Row C Row D Row E Row F Row G Row H 
Control OD's: 1.861 1.593 1.656 1 550 1.556 1.691 0 362 0.384 
Statistics 
Ant f TY YP TH PN PA Ant 
Result Summary by Delta 
well OD Delta Res AD Broad 
P. 3, Rb 
3: 9.399 9.963 E: s C'J 34 9 41 P., F, -, _- _, 
33 
19 2.1312.1,3133 13 51 R', ...:, r 
Q1 
35 1.895 1.764 F8 43 R1, ý(-ýT7 31, Q3 
42 1.731 1 . 641 F. ä 13 60 014L 1', 339, R2, P. 6 
_3 1.687 1.50E F'3 54 62 04,,,,. 
46 1.608 1.4'- .. _ 8 
37 1.475 1.344 .. 
II 
.3 18 ,-i LJ .,. 
41 1.457 1.32c 13 
20 1.397 1. _55 F__ __ 54 ,: RL 
34 1.379 1.249 63 R4, 
. 335 1.2C4 PPCS 29 41 
17 1.234 
1.103 PCS _3 C8 58 38 
.4 . 200 1.069 
PCs 32 5 14 F4, F, "_, -9, Q3 
4 1.1 2,0.996 P00 19 ._-P. 3 
99 1.091 0.960 POS 25 .1 F1: 6ý , 92,31 
12 1.064 0.933 PCS 31 P9,,, -üf 
3 1.037 0.906 POS 1 
21 1.035 0.904 PCs 3 .. _.. _, 
ý] 
15 0.982 0.85, PCS 1 6: 
.8^.. 9-4 0.843 PC 33 45 53 0', .. _ 
'a,,,, 
Wall OD D. lta Res AB Broad 
14 0.8 34 42 21S .J., . 
31 0.854 0. '23 PCS 1 :.,, Q1 
36 0.836 0.705 PCS 24 ,. - P4,91,93 
40 0.828 0.697 PCs 01 18 R4, , ý1 
44 0.795 0.664 r_3 
I 
-. 19 P1',,, ., .' 
26 0.789 5.653 E15 2- 44 R7, P. _, 
n 01,91 
1: 0.150 0.619 8_, ,, P4,,,, C, 
ý"_+ 
13 0.661 0.530 77E3 3 :3 50 55 P. 3,0_ 91 
27 0.612 0.481 0E3 26 44 39 R11, F:;,, i, 1', ,, 91 
30 0,580 0.449 NEG 3 11 18 52 R11, R17, Q_, 93, R3, Q3 
7 0.560 0.429 NEG 32 38 R11,,, 27, Q3 
45 0.555 0.424 NEG 24 28 44 49 R1, R11,95,97,91, Q3 
13 0.538 0.407 NEG 1 57 0,93 
48 0.419 0.348 NEG 24 51 R-,,,, 19, Q3 
6 0.414 0.283 NEG 23 14 R4 ,,,, Q9,23 
10 0.411 0.290 NEG 24 60 89,,,, 29, 
8 0.354 0.223 NEG 29 61 811,,, Q7, .3 
16 0.314 4.193 NEG 24 26 51 61 R9,,,, 93, Q3 
43 0.250 0.119 NEG 29 32 45 31 R4, Pi1,97, Q8, Q3 
0.206 3.375 NEG 1 4: 011,,, , 
Figure 4.6 SOFT-STAT report showing analysis 
using class I+ class II panel 
I TP PP TH PN PR "t I TP PP TN PN P P. 
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Date: 26K)6Q7 Page: 1 
Sample Report Tlrne: 10: 17: 22 
Date: 24110196 Run ID 24110196-1 Lot Class 1+11 
Patient ID: X147 Name: 
Sample ID W143 Draw Date: 22/07188 Tech: ANDREA Row G 
rest Parameters Mean PR: 1.504 
Lot Caic. Class NII X Ratio Factor: 0.35 
Q Invalid Sample 
Dilution: 1: 101 Analysis: FisherTall - Cutoff Used: 0.526 
Q Invalid Run 
PRA: 17% 
Interpretation: 
Row A Row B Row C Row D Row E Row F Row G Row H 
Control OD's: 1.669 1.519 1.552 1 337 1.400 1 544 0 420 0439 
Statistics 
Wit 1 SP PP TN PN PR Ant 
Result Summary by Delta 
Well OD Do1ta Res AB Broad 
34 :. 074 7.352 POS .. .3 R4, R. i 5r 36, Q9" P. 2, 
3: 0.955 0.933 POS ? .. _ 91, , Q5,19, C1,33 
38 0. '99 :. 666 FCS .... Q"I 
2_ 0.741 3.62`, P, _5 . 
ýj`\ --", ", Q`. " ": 1 ^3 
'. 666 0.544 F: S 
D 
26, Q1, R2 
30 0.663 0.541 F: :S .-- ? __"-. "0-, `, R%" 
Q3 
16 0.583 2.461 NE? 
a 
-. - .., """C?, 33, 
.,. 
0.591 7.459 NEG _ ,. ,-, -. "QCr : 11, P3, .1 
47 0.544 1.422 NEG 1 Q7, P. 6,31 
4- 1.498 3.3'6 NEG 24 44 43 5. " 0.1,35,3'" ,. 1, 
23 0.493 0.371 NEG 2 54 62 R4 ""34 
44 1.4 6 2.354 NEG 
23 50 18 R17"  3, ,,, 53 
2.386 ... _64 NES 
1 30 9 63 R13, P: ', QO, Q6, R3, R6 
_5 0.383 .. 261 NEi 2 29 8 50 R", R1'"Q,,,, P. - 
43 .. 3'4 .. _52 
4E9 29 32 45 35 R4, R1:, 87 31,13 
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CHAPTER 5 
HLA MATCHING AND ANTIBODY PRODUCTION 
IN TRANSPLANTED PATIENTS 
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Previous studies have investigated antibody production in transplanted 
patients, especially in relation to the occurrence of rejection episodes. Few studies 
have looked in detail at the occurrence of antibodies post transplant and the effect of 
HLA matching on antibody production in a large population of patients. Most studies 
have limited investigations to HLA class I specific antibodies and there is little data 
on the prevalence of HLA class II specific antibodies resulting from graft loss. 
Using the techniques developed and evaluated in this study an investigation 
into antibody production in patients with failed grafts has been undertaken. The 
Flowscreen technique provides the most sensitive method for antibody detection. 
Previous studies have used cytotoxic techniques and it is possible that this may have 
resulted in failure to detect HLA specific antibodies which can be detected by more 
sensitive methods. 
The population chosen for the study comprised all adult recipients of primary 
renal allografts between 1984-1993. A total of 460 transplants in 177 female and 283 
male recipients were performed. All patients were transplanted in a single unit and 
received Cyclosporin A and prednisolone immunosuppression. Other 
immunosuppressive agents varied according the current policy during this period. 
Patient outcome for the study was determined as current status in January 1995 and 
was recorded as functioning, failed or died with function. No distinction was made 
between immunological and non-immunological causes of graft failure. 
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Cytotoxic screening was routinely performed on all samples collected 
following graft failure until such time as the patient was re-transplanted, died or was 
transferred. The results were analysed and samples were selected for further analysis 
on the basis of cytotoxic screening results. Patients with CDC panel reactivities of 
over 50% with clear HLA specificity in the first sample collected following graft 
failure were not considered to require further analysis. All other patients had samples 
screened by additional techniques. The first sample collected following the date of 
graft failure was chosen for analysis on all cases and subsequent samples were 
screened if a negative result was found with the first sample. 
Samples were not routinely obtained from patients with functioning 
transplants. However during an 18 month period from January 1990-June 1991 post 
transplant samples were collected for another study. Samples were obtained at 
between 2 and 12 months post transplant. For this study a sample taken as close as 
possible to 6 months post transplant was screened to provide data on patients with 
stable function. No samples less than 2 months post transplant were screened. 
Flowscreening of EBV cell pools using the EPICS-XL was used as the 
principle technique for screening samples which required further analysis. Samples 
from patients with functioning grafts were screened by Flowscreen only. The majority 
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of samples from patients with failed grafts were screened by both Flowscreen and 
PRA-STAT. 
Matching data was based on the recipient and donor types recorded in the 
patients records. Where no HLA class II type was recorded for a patient a sample was 
requested if the patient was still living. All samples received were class II typed by 
PCR-SSP as described in section 2.7 and the results were used to determine the 
matching for those patients. Where no patient samples were available for typing or in 
the few cases of incomplete donor types the transplants were excluded from matching 
analyses. 
Suitable post transplant samples were available from 46 patients with 
functioning grafts The samples were collected between 52 and 386 days post 
transplant with a mean collection day of 140. The patients were transplanted between 
January 1990 and June 1991 and all still had functioning grafts in January 1995. Two 
of the forty six samples were found to be positive by Flowscreen. In both cases the 
reactivity was against only 1 of the 2 cell pools used with percentage reactivity against 
this pool of 44.7% and 19.05% respectively. 
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5-6.2 Failed graft 
5 2.1 Screening Strategy 
Between January 1984 and December 1993 460 primary transplants were 
performed. One hundred and fourteen had failed by the census date in January 1995 
(48 in female and 66 in male recipients). Of these 9 patients were excluded from the 
analysis because either no post graft failure samples had been obtained or because no 
serum remained to carry out further screening in addition to the initial CDC screen. A 
total of 105 patients were analysed for this study. In 31 cases the results of CDC 
screening did not indicate a need for further analysis, in the remaining 74 cases one or 
more samples were screened by additional methods. Overall 64 patients were 
screened by both Flowscreen and PRA-STAT, 9 by Flowscreen and 1 by PRA-STAT 
in addition to the CDC screening. Table 5.1 (p 159) shows the screening methods used 
for samples split into 2 groups of those above and below 50% CDC PR. A small 
number of samples with CDC PR of >50% had further screening performed to 
confirm whether antibodies were IgG or IgM where no DTT testing had been carried 
out. 
5 6-2.2 Comparison of Screening Methods for Antibody Detection 
Tables 5.2 -5.4 (p 160-162) show the correlation between the each of the 3 
methods for the detection of antibody. There was a statistically significant correlation 
between all 3 methods for the detection of antibody. Thirteen samples were CDC 
positive, flowscreen negative (table 5.2, p160), all of these were IgM antibodies as 
confirmed by additional DTT or PRA-STAT screening. Nine of the ten CDC positive 
pRA-STAT negative samples were IgM. PRA-STAT detected HLA specific 
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antibodies in 4 patients where CDC screening did not detect any antibody formation. 
These 4 patients also had HLA specific antibody detected by Flowscreen. There was 
one patient for which Flowscreen detected HLA specific antibody production before 
either CDC or PRA-STAT as determined by testing sequential samples. In addition to 
this patient PRA-STAT failed to detect HLA specific antibodies in 2 patients who 
were CDC and Flowscreen positive. There were 3 patients where Flowscreen was 
positive but there was no evidence of HLA specific antibody production at any time 
following graft failure by CDC or PRA-STAT screening of sequential samples. 
Sixty three patients had samples tested by all three methods (table 5.1, p159). 
Twenty one were negative by all three methods and a further nine were shown to have 
only IgM antibodies. Of the remaining 33 patients there were 3 patients where 
Flowscreen demonstrated antibodies not detected by CDC or PRA-STAT. Thirty 
samples had detectable IgG HLA specific antibodies by at least 2 of the three methods 
used. All had CDC PRs of < 50%. The PRs detected by Flowscreen &/or PRA- 
STAT were >50% in 23 of these with only 8 patients where all 3 methods showed a 
PR of <50%. Figure 5.1 (p174) demonstrates the differences in PR determination by 
the 3 methods. Statistical analysis of the panel reactivities were carried out for all 
samples where either 2 of the 3 or all 3 methods were used. A total of 73 cases were 
tested by both CDC and Flowscreen, 63 by Flowscreen and PRA-STAT and 64 by 
CDC and PRA-STAT. Table 5.5 (p163) shows the mean PRs determined for all the 
samples tested for each comparison and the results of the t-distribution test and the 
Wilcoxon matched-pairs signed ranks test. The results of the parametric and non- 
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parametric analyses are very similar for each comparison indicating that the 
distribution of the within samples differences is normal and that the parametric 
analysis is therefore valid. The results show that there is no significant difference 
between the PRs determined by CDC and PRA-STAT (p=0.176) whereas the 
Flowscreen PRs are significantly higher than those determined by either CDC or 
PRA-STAT (p<0.001). 
The results of the Flowscreen gives the percentage binding within the positive 
analysis gate. A background binding of up to 10% is taken to be an acceptable level 
with greater than 10% above the background being considered positive. Therefore 
samples which are effectively classed negative will still be recorded with a PR of 
between 0 and 19%, in practice the majority of negative samples have percentage 
binding of 5-15%. This could account for the significantly higher PRs detected by the 
Flowscreen method so an analysis of the results was carried out after subtracting 10% 
from the Flowscreen results. There was a difference between the parametric and non- 
parametric test results when this analysis was carried out indicating that the non- 
parametric test was the appropriate method. The results of the Wilcoxon test showed 
that there was still a significant difference between the results of the Flowscreen and 
CDC (p=0.002) and PRA-STAT (p=0.006) methods for detecting panel reactivity 
when the background binding was taken into account. 
The panel reactivities of the antibodies produced in the positive patients 
screened by all 3 methods are illustrated in Figure 5.1 (p 174). This graphical 
illustration of the results demonstrates the higher PRs produced by the Flowscreen 
technique, this is particularly evident in samples with CDC and PRA-STAT PRs of 
less than 50%. However there are a number of samples with high Flowscreen and 
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PRA-STAT but low CDC PRs. This apparent similarity in PRs determined by 
Flowscreen and PRA-STAT, despite the significant difference between the 2 methods 
which was shown by statistical analysis is confirmed by performing a correlation test 
for the 3 methods. Whilst correlation coefficients are not a suitable method for 
determining agreement between different methods of measuring the same factor they 
do give a measure of the likelyhood of being able to predict the value of one variable 
from the known value of another variable. The correlation coefficient for Flowscreen 
and PRA-STAT is 0.86 compared with 0.64 for CDC and Flowscreen and 0.54 for 
CDC and PRA-STAT. 
Analysis of specificity determination by PRA-STAT was compared with the 
class I specificities detected by CDC. In only 3 of the 30 patients were the CDC and 
PRA-STAT specificities concordant. In the majority of the patients PRA-STAT 
detected HLA class II specific antibodies in addition to the HLA class I antibodies 
detected by both CDC and PRA-STAT (26/30). In 8 of these patients PRA-STAT 
also detected antibodies to HLA class I antigens which were not shown by CDC 
screening, and one patient with no HLA class II specific antibody had additional class 
I specificities detected by PRA-STAT. Table 5.6 (p164) details the HLA specificities 
of the antibodies detected in the 9 patients with additional class I specificities. In 4 
cases there was no evidence of any HLA specific antibody production by CDC 
screening and in another patient with a CDC PR of 42% there was no apparent 
specificity which could be determined by CDC testing. PRA-STAT failed to detect 
class I specificities found by CDC in 2 cases, patient 14 shown in table 5.6 (p 164) had 
a CDC detectable B51 antibody. Another patient had an antibody specific for HLA B7 
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which was detected by CDC but not by PRA-STAT, antibody was detected by 
Flowscreen in this patient. 
Although PRA-STAT detected additional specificities compared with CDC in 
the majority of patients there was no significant difference in the PRs determined by 
the 2 methods. This could be due to differences in the composition of the panels used 
for the screening. Table 5.7 (p165) shows the percentages of selected HLA antigens 
in the panels. Random panels were used for CDC screening, therefore a mean of five 
40 cell panels and five 60 cell panels were taken as representative of the CDC panels 
used. HLA Al, A29, A30, A31 and A32 are found in approximately equal proportions 
of each panel whereas there is a slightly higher proportion of A23 and A24 in the 
PRA-STAT panel. However the other antigens surveyed appear at a higher proportion 
in the CDC panels. These results show that for some of the commonly found antigens 
which elicit antibody responses in the population studied the CDC PR would be 
expected to be higher than the PRA-STAT PR if exactly the same antibody 
specificities were detected by both methods. This could explain the fact that PRA- 
STAT PRs are not significantly higher than those determined by CDC despite the 
additional specificities detected. 
The Flowscreen method produced PRs which were significantly higher than 
those given by CDC and PRA-STAT even taking into account the background binding 
present. Analysis of the actual and expected PRs determined by Flowscreen and PRA- 
STAT for a number of cases indicates that Flowscreen often gives higher percentage 
binding than would be expected from the antibody specificity. The expected PR is 
based on the frequency of the antigens in the individual pools and the expected mean 
percentage binding for the 2 pools. A range is given to allow for the background 
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binding of up to 10%. Table 5.8 (p166) shows the results of the analysis. This 
indicates that the PRA-STAT method, used to determine the antibody specificity gives 
a PR close to the expected result, with 1 or 2 false positive or negative results 
accounting for the slight difference. The Flowscreen however often produces PRs 
which are considerably higher than those which would be expected from the known 
specificity and pool composition. This could be accounted for if Flowscreen detects 
additional antibody specificities not found on PRA-STAT screening, although it is not 
possible to determine if this is the case using the methods available. 
5.6.2.4 HLA Specific Antibodies Resulting from Graft Failure 
The results of the screening carried out showed that 21 of 105 patients at no 
time produced any detectable antibody following graft loss. Eighty four patients were 
shown to have detectable antibody. Twelve of these patients produced IgM antibody 
with HLA specificity being found in 5 cases. Four patients produced IgM antibody 
specific for mismatched donor antigen (A2 in 2 cases, B8 and DR4 in I case each), 
one patient produced an IgM antibody specific for A9, which was not present on the 
allograft. Three patients produced antibody which was detected by flow cytometry 
only, with antibody binding to 30,35 and 36% of the cell pools respectively. The 
remaining 69 patients had HLA specific IgG antibody with specificity for mismatched 
donor antigens in 67 of the 69 cases. In forty of the 67 patients producing donor 
specific antibody additional non-donor specific antibodies were also demonstrated. 
The impact of HLA-specific IgG antibody on future transplantation in these 
patients was examined. Table 5.9 (p 167) shows the retransplant rates in the antibody 
positive and negative groups. Patients who never produce antibody were more likely 
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to receive a second graft, 58.3% compared with 34.8% of those patients with HLA 
specific IgG. The function of second transplants was also investigated with regards 
the antibody status of the patients. Forty five patients had received second grafts at 
the time of writing, table 5.10 (p 168) shows graft outcome in the antibody positive 
and negative groups. The cumulative graft survival in patients with no evidence of 
antibody production is 80.9% which is significantly higher than the 41.7% of regrafts 
currently functioning in patients with antibody. The relationship between antibody 
specificity, and mismatching on the first and second grafts was investigated. Table 
5.11 (p 169) shows that there is no significant effect of repeating a previous mismatch 
on a second graft. There were 16 patients who received a second transplant with 
repeat mismatches. Ten patients received grafts with repeat class II mismatches, 3 of 
which also had repeat class I mismatches, 5 of these 10 grafts failed. One failed graft 
was shown to have produced antibody to the repeat mismatch, I was not tested for 
class II antibody and 3 had no detectable class II antibody. A further six patients had 
repeat class I mismatches, only 1 of which failed. 
The policy regarding repeat mismatches during this time would ensure that a 
mismatch would not have occurred if CDC screening had demonstrated an antibody 
was produced to that mismatched antigen. The results of the PRA-STAT screening 
demonstrated antibodies specific for HLA antigens, not detected by CDC, which 
were present on subsequent grafts in 3 patients, all 3 grafts failed. Only one of these 
was due to a previous mismatched antigen (DQ 1), one was a pregnancy induced 
antibody specific for Al and the remaining antibody was specific for DQ3. Six of 
eleven grafts with no evidence of antibody specific for the mismatched antigens on the 
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second graft failed. In the remaining 10 patients the class II antibodies had not been 
determined or the donor class II type was not known. 
Four of the five patients who produced IgM HLA specific antibodies received 
second grafts, one of which failed. None of these grafts were mismatched for the 
antigen to which the recipient was sensitised by the first graft, although 2 of the grafts 
did have repeat mismatches to which no antibody was detected following failure of 
the first graft (an Al mismatch in the patient with B8 antibody and a DQ1 mismatch 
in the patient with DR4 antibody). Both grafts were functioning at the census date. 
Figure 5.2 (p175) illustrates the overall graft survival in all second transplants 
performed between 1984 and 1993 together with that for first grafts. The survival in 
regrafts is no different to that of first grafts. This suggests that sensitisation due to a 
previous failed transplant does not significantly decrease graft survival and that the 
relatively small number of antibody positive patients who received both first and 
second grafts during the study period may not be representative of the overall 
experience for regrafts. 
The analysis of antibody levels and HLA matching was performed using the 
highest recorded PR following graft failure. In some cases the PR was found to 
continue to rise over several months after significant antibody production was first 
detected, and specificity analysis showed that these antibodies were related to graft 
loss. When patients were found to have a marked rise in antibody post-graft failure 
due to a subsequent blood transfusion the highest PR prior to the transfusion was used 
for the analysis. Table 5.12 (p170) shows the mean PR for the different DR mismatch 
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groups and table 5.13 (p 171) for A, B, DR mismatch. There were no cases of 0 
A, B, DR mismatched grafts in the failure group. The Kruskal-Wallis 1-way analysis 
of variance was used to determine whether there was a significant trend across the 
mismatched groups for antibody production. The results shown on tables 5.12 (p 170) 
and 5.13 (p 17 1) indicate that when DR matching alone is analysed the increase in PR 
with number of DR mismatches is not statistically significant, however when 
mismatching at A, B, DR is considered there is a significant trend for increasing 
antibody levels with increases in the number of mismatched antigens (pß. 0257). 
The influence of HLA matching on graft survival was analysed for primary 
transplants performed between January 1984 and December 1993. There were 395 
donor recipient pairs with complete matching data for HLA A, B, DR. Sixty five cases 
were excluded from the analysis because DR types were not known for one or both of 
the pair. The cases analysed contained 364 cadaveric transplants and 31 living related 
transplants. An overall analysis and separate analyses for cadaveric and living donor 
transplants were performed. All failures and all cases of death with function were 
classed as graft losses for the survival analysis. 
Figures 5.3,5.4 and 5.5 (p 175-177) show the actuarial survival for all grafts, 
cadaveric and living donor transplants respectively according to DR match. Table 
5.14 (p172) shows the cumulative graft survivals for each of the groups. Although 
there is 0% graft survival in the living donor grafts mismatched for both DR antigens 
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this relates to only a single case. This is seen in figure 5.4(p176) as curtailment of the 
appropriate line at the time of this failure. The survival in the 0 and 1 DR mismatch 
groups are less than 2 percentage points different. There is an overall difference of 
over 20% in the cumulative survival of the cadaveric grafts. Log rank analysis of the 
Kaplan-Meier curves for trend show that for all 395 transplants there is a significant 
association between DR mismatch and graft failure (p = 0.0035). Individual log rank 
tests show that there is no significant effect for matching in the living donor group and 
that the overall significance is a result of differences observed in the cadaveric group. 
Figure 5.6,5.7, and 5.8 (p 179-181) show the actuarial survival curves for all 
grafts, cadaveric and living donor transplants respectively according to A, B, DR 
mismatch. There were no living donor grafts mismatched for more than 3 antigens. 
The overall cumulative survival for the living donor grafts is 87.1 % compared with 
63.46% for cadaveric grafts. Table 5.15 (p173) shows the cumulative graft survivals 
for each group according to total mismatches. Log rank analysis of the Kaplan-Meier 
curves for trend show that for all 395 transplants there is a significant association 
between A, B, DR mismatch and graft failure (p = 0.0006). Individual log rank tests 
show that there is no significant effect for matching in the living donor group and that 
the overall significance is a result of the differences observed in the cadaveric group. 
In the no mismatch group there was a single graft loss due to the death of the patient, 
with a functioning graft at over 7.5 years post-transplant. The actuarial survival curve 
therefore shows graft survival at 100% until the time of this loss. There are no further 
observations in this group beyond this time point therefore the line is curtailed. 
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CDC + CDC + CDC + CDC 
Flowscreen + Flowscreen PRA-STAT 
PRA-STAT 
CDC PR < 50% 60 7 0 0 
CDC PR > 50% 3 3 1 31 
Table 5.1 Screening techniques used for determining antibody production in patients 
following transplantation 
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CDC + CDC - 
Flowscreen + 27 8 
Flowscreen - 13 25 
x2 = 11.88 p<0.001 
Table 5.2 Comparison of Flowscreen and CDC screening for the 
detection of antibody 
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CDC + CDC - 
PRA-STAT + 26 4 
PRA-STAT - 10 24 
x2 = 18.97 p<0.0001 
Table 5.3 Comparison of PRA-STAT and CDC screening for the 
detection of antibody 
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PRA-STAT + PRA-STAT - 
Flowscreen + 29 5 
Flowscreen - 0 29 
x2 = 42.46 p<0.0001 
Table 5.4 Comparison of Flowscreen and PRA-STAT for the detection 
of antibody 
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mean % PR t-test Wilcoxon test 
CDC 20.77 
vs vs t= -4.61 , p<0.001 z= -4.5 p<0.001 
Flowscreen 37.05 
PRA-STAT 24.63 
vs vs t=7.24 p<0.001 z= -5.61 p<0.001 
Flowscreen 39.75 
CDC 20.09 
vs vs t=-1.37 p=0.175 z=-1.35 p=0.176 
PRA-STAT 25.70 
Table 5.5 Comparison of the percentage panel reactivities determined by different 
screening methods 
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tl ý b - -------------------------------------------- f 
4 A2,1340. Cw3, 91%, none 87'70 
-- ----------- 
A2, ('\O, 
DR4,7, DQ3 DR4,7 D Q3 
13 A1, B49,61 Cw2 42% none apparent 87% A9, B15 B60,61 
DR5,6 DQI 
16 A1,29 B8,51 44% B51,52 26% B8,51,52 
Cw2 DR4,14 
14 A2, B44,51 28% B44,51 30% A2, B44 DR4,7 
DR4,7 
18 A2 B18 DR3 0% 91% A2, A19, B51,52 
DR3 
30 A1,3 B7,8 Cw7 27% Al B8 96% A 1,3,19 B7,8 
DR3 DR3 D Q3 
68 A1,2 B7,37 7% none 57% A2 DR4 DQ3 
DR4 
78 A24 B27,39 39% A24 57% Al DR2,4 
wl DR4 
99 Al 1 B7 DR2,5 0% 91% All B7 DR2,5 
D1 
Table 5.6 Panel reactivities and antibody specificities determined by CDC and 
PRA-STAT screening in patients with additional class I specificities 
detected by PRA-STAT 
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HLA Antigen 40 Cell CDC panel 
(mean of 5 panels) 
60 cell CDC panel 
(mean of 5 panels) 
PRA-STAT panel 
Al 22.5 17.6 17.4 
A2 56.5 50.0 30.0 
A3 28.5 30.6 10.9 
A23 3.5 2.3 8.7 
A24 12.0 11.6 17.4 
A29 6.0 5.0 6.5 
A30 9.0 9.0 6.5 
A31 3.0 9.0 6.5 
A32 7.5 10.3 8.7 
B7 13.5 16.3 6.5 
B8 20.5 19.6 8.7 
B35 19.5 16.3 4.3 
B44 18.5 18.0 10.9 
B60 13.0 9.6 6.5 
Table 5.7 HLA antigen frequency of selected antigens in 40 and 60 cell CDC and 
PRA-STAT panels 
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Antibody Flowscreen PRA-STAT 
specificity Actual %PR Expected %PR Actual %PR Expected %PR 
A24 DR7 50 38-48 30 33 
Al B12 DR2 83 52-62 57 52 
B57 DR7 45 24-34 22 17 
B51,52 75 14-24 17 22 
B8,51,52 50 24-34 26 24 
A23 B44 DR7 71 28-38 41 33 
DR4 DQ3 71 43-53 54 57 
Table 5.8 Actual and expected percentage panel reactivities for Flowscreen and 
PRA-STAT screening of samples containing HLA specific antibody 
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IgG antibody positive IgG antibody negative 
Regraft 24 21 
No regraft 45 15 
x2 = 4.44 p=0.033 
Table 5.9 HLA-specific IgG antibody and regrafts in patients with failed primary 
transplants 
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antibody positive antibody negative 
working 10 17 
failed 14 4 
x2 =5.66 p=o. oi7 
Table 5.10 Second graft outcome in patients with or without HLA-specific IgG 
antibody following failure of a first transplant 
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repeat mm no repeat mm 
working 10 17 
failed 6 12 
x2=0.004 p=0.95 
Table 5.11 Graft outcome in patients receiving second transplants with or without 
repeat mismatched antigens 
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DR Mismatches No. patients Mean maximum PR Standard deviation 
0 5 26.60% 42.69 
1 54 50.98 % 34.51 
2 36 61.58% 35.74 
Kruskal-Wallis 1-way ANOVA x2 = 4.61 p=0.0998 
(corrected for ties) 
Table 5.12 HLA-DR mismatch and mean percentage panel reactivity following graft 
failure 
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A, B, DR mismatches No. patients Mean maximum PR Standard deviation 
1 2 0% 0 
2 6 31.33% 26.57 
3 21 49.43% 37.36 
4 21 63.81% 34.11 
5 33 51.36% 34.79 
6 12 70.17% 34.72 
Kruskal-Wallis 1-way ANOVA x2 = 12.76 p=0.0257 
(corrected for ties) 
Table 5.13 HLA-A, B, DR mismatch and mean percentage panel reactivity following 
graft failure 
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DR 
mismatch 
No. cases Overall graft 
survival 
Cadaveric graft 
survival 
Live donor graft 
survival 
0 68 77.94% 75.44% 90.91% 
1 216 67.59% 65.48% 89.47% 
2 111 53.15% 53.64% 0% 
Table 5.14 Cumulative graft survival and HLA-DR matching 
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A, B, DR 
mismatch 
No. cases Overall graft 
survival (n=395) 
Cadaveric graft 
survival (n=364) 
Live donor graft 
survival (n=31) 
0 13 92.31% 85.71% 100% 
1 18 77.78% 78.57% 75.00% 
2 51 82.35% 80.49% 90.00% 
3 85 62.35% 59.46% 81.82% 
4 103 66.99% 66.99% - 
5 101 56.44% 56.44% - 
6 F 24 45.83% 45.83% - 
Table 5.15 Cumulative graft survival and HLA-A, B, DR matching 
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CHAPTER 6 
DISCUSSION, CONCLUSIONS AND PLAN OF FUTURE STUDY 
182 
6.1 Discussion 
The initial aim of this study was the development of a flow cytometric 
technique for antibody screening which would fulfil the requirement for a screening 
method which was as sensitive as the final crossmatch method. In order for the 
technique to be suitable for use as a routine method it was necessary for relatively 
large numbers of samples to be tested against a suitable number of different target 
cells in a short period of time. For this reason the approach taken was to use pooled 
cells which would allow samples to be screened against several different cells at one 
time. The initial idea was to use pooled platelets. Platelet pools have been used in 
many studies as a target which will absorb HLA class I specific antibodies present in 
serum samples onto the surface antigen, effectively removing the antibody from the 
serum. This method has been used to prove that antibodies are specific for class I 
antigens by screening before and after absorption. In addition it had been suggested 
that platelets were a suitable target for flow cytometric crossmatching by Wang et al 
(1989). This study showed that the results of flow crossmatching with donor platelets 
correlated better with graft outcome than did the lymphocyte FCXM, possibly due to 
a number of `false positive' T cell flow crossmatches due to non-HLA specific 
antibodies. 
Whilst the results of the first flow screen with pooled platelets did show a 
significant correlation with CDC screening results for antibody detection subsequent 
tests showed that the platelets produced inconsistent results and that there was an 
unacceptable number of false negative results with the platelets.. Therefore this 
method failed to fulfil the requirement for a more sensitive method than CDC to 
correspond with the more sensitive FCXM crossmatching technique. In addition there 
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was little correlation between the percentage binding to platelets and the CDC panel 
reactivities. The use of CLL cell pools produced more satisfactory results with a 
strong correlation between the flow cytometric method and CDC techniques but with 
an apparent greater degree of sensitivity of the flow cytometric method as shown by 
the increasing number of flow positive CDC negative results obtained with higher 
serum dilutions. The use of CLL pools was thus confirmed as a suitable method for 
screening with a sensitivity to match that of the flow crossmatch. 
Although the CLL cells had proved an ideal target the supply of cells was 
limited and it was decided to investigate the use of cultured cells which could be 
stored in liquid nitrogen and then grown up in large numbers whenever required. This 
also provided the opportunity to chose cell lines with specific HLA types from the 
large catalogue of such cells which are available. It was therefore possible to 
construct pools so that most HLA antigens were represented. Testing of EBV cell 
pools showed that these were also suitable for screening samples for both HLA class I 
and class II specific antibodies using the technique developed with the CLLs. 
The flow method was found to be able to detect antibodies which CDC had 
shown to be directed against `uncommon' HLA antigens which were represented on 
only 1 of the cell lines contained in the pool. It was also found that positive results 
were sometimes obtained even when the antigen to which the antibody was thought to 
be directed (from the CDC screening results) was not present in the pool. The reason 
for this could not be clearly demonstrated but it is possible that antibodies which 
appear to be monospecific or directed at a limited number of discreet HLA antigens 
by CDC techniques are in fact more widely reactive when a more sensitive technique 
is used. It may be that the antibody detected by CDC is present in the serum at a 
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higher titre than additional antibodies, directed at other antigens. These could be 
antigens within recognised crossreactive groups, sharing epitopes with the principle 
target antigen. Lower titre antibodies could be detected by the more sensitive flow 
cytometric technique. 
Another possibility is that the antibodies detected by the flow cytometric 
technique may be of a non-complement fixing IgG sub-type which would not 
therefore be detected by the complement dependant technique. Sumitran-Karuppan et 
a1(1992) had investigated IgG subclasses in positive flow cytometric crossmatches. 
Patients with negative CDC crossmatches but positive flow crossmatches were found 
to have an increased risk of rejection and the subclass analysis showed a mixture of 
different combinations of subclasses with sometimes high titres of non-complement 
fixing IgG4 together with lower titre IgGI and IgG3. This analysis suggests that both 
antibody titre and subclass may be factors in the observed sensitivity of the flow 
cytometric screen. 
The results had shown flow cytometric analysis of cell pools to be a suitable 
method for antibody detection which met the requirements set at the start of the study. 
Confirmation that the development of this particular technique as an approach to 
screening was appropriate was given by the concurrent development of similar 
techniques by other workers. Cicciarilli et al (1992) used a pool of 10 peripheral 
blood lymphocytes for screening by flow cytometry, allowing the detection of HLA 
class I antibodies. The method was used to investigate antibody status of the pre- 
transplant serum of regraft recipients. The majority of samples were positive by both 
CDC and the flow technique, flow cytometry detected antibody in some samples 
which were CDC negative and CDC detected IgM antibodies in some flow negative 
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samples. These results are similar to those seen when developing the Flowscreen 
technique with CLL pools and with the EBV pools. 
Shroyer et al (1995) used a pool of 6 peripheral blood lymphocytes selected 
such that antigens within each of 14 cross reactive group were represented. The results 
of this study showed a strong correlation for antibody detection between CDC and the 
flow cytometric method, with flow cytometry detecting a significant number of extra 
positives not detected by CDC. The mean PR was higher by flow cytometry than by 
CDC for the samples which were positive. This finding of higher reactivity with the 
flow cytometric screening with the use of a limited pool where only CREGs were 
represented rather than individual antigens would support the hypothesis that flow 
cytometry detects cross reactive antibodies which are not detected by CDC. This 
would suggest that in a large majority of cases the reactivity of the antibodies is far 
broader than is indicated by the results of CDC screening and monospecific antibody 
production elicited by recognition of a single private epitope is rare. 
ELISA screening was introduced as a commercially available screening 
method by SangStat. Buelow et al (1995) published details of the development of the 
method and of a comparison with CDC screening techniques carried out in 5 
laboratories. The reported concordance between PRA-STAT and CDC screening for 
detection of HLA class I specific antibodies was good with inter-laboratory agreement 
and very high levels of reproducibility of results. A number of reports appeared in the 
literature shortly after the method became available with varying views on the ability 
of the method to detect HLA class I specific antibodies. Kerman et al (1996) reported 
good correlation between PRA-STAT and CDC for the detection of antibodies. In 
this study the antibody status of patients prior to transplant was examined and it was 
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shown that there was a stronger correlation between patients with PRA-STAT 
detectable antibody and graft rejection than with CDC detectable antibody. However 
no distinction between IgG and IgM antibodies detected by CDC was made when the 
clinical significance of the antibodies was investigated despite the identification of 
IgM antibodies being commented on when the correlation between the 2 methods for 
antibody detection was made. The comparison of the methods for clinical 
significance is therefore flawed as IgM autoantibodies are included in the CDC 
detectable group despite the well documented evidence that these antibodies are not 
clinically significant. A later study by Monteiro et al (1997) did distinguish between 
IgG and IgM antibodies detected by CDC in making a similar comparison and found 
that patients with PRA-STAT detectable antibody pre-transplant did have a higher 
proportion of graft losses compared with patients with CDC detectable IgG antibody. 
Zachary et al (1995) whilst finding the method to be reliably reproducible and 
correlating well with CDC for detection of antibody did not find that the specificity 
determination by PRA-STAT corresponded well with the CDC determined 
specificities In only 12 of the 66 sera which were positive by both methods were the 
antibody specificities found to be identical. There were examples of samples which 
were CDC positive/PRA-STAT negative, PRA-STAT positive/CDC negative and 
many where the specificities simply did not agree. Bryan et al (1995) compared PRA- 
STAT with CDC screening and an in house ELISA method which utilised solubilised 
HLA antigens from platelet pools. The local ELISA method was found to correlate 
closely with an AHG CDC screening technique whereas PRA-STAT had a lower 
correlation. 
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PRA-STAT was investigated as a part of this study initially in the hope that 
the method could be used to determine HLA class I specificties in samples which 
were known to contain IgG antibodies from the results of the Flowscreen. Initial 
testing showed a good correlation for antibody detection in most cases, although there 
appeared to be a problem with PRA-STAT being unable to reliably detect IgG 
antibodies in sera which also contained high titre IgM antibody. This had also been 
commented on in the report by Zachary et al (1995). Although antibody detection 
appeared to correlate well there were considerable differences in the specificities 
found by PRA-STAT and CDC. The very strong correlation between Flowscreen and 
PRA-STAT was the first indication that the ELISA technique was detecting 
antibodies other than those found by the conventional CDC technique for class I 
screening. In 15 of 16 patients with serial samples the results of Flowscreen and 
PRA-STAT for PR mirrored each other exactly. It was therefore not surprising when 
it was discovered from the manufacturers that rather than having isolated HLA class I 
antigen captured on the plates there was also class II antigen present. 
An important factor in establishing the presence of class II antigens on the 
ELISA plates was the HLA typing, by PCR-SSP, of the cell lines. Whilst providing 
the details of the class II types the results also showed that there were some mistakes 
in the original class I types of the cells which had been used in all the analysis 
software provided by the manufacturers for use with the kits. The veracity of the 
genotypes rather than the provided phenotypes was shown by analysis of the class I 
specificities found in some of the samples in this study. The incorrect class I types 
used in all the previous studies, including the first reports of the technique and the fact 
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that HLA class II antigens were present make the strong correlations found in some 
studies somewhat surprising. 
Kerman et al reported an 82% agreement in antibody specificity determination 
between CDC and PRA-STAT, whereas Zachary found identical specificities in less 
than 20% of the samples tested. Zachary found that there were a number of cases 
where PRA-STAT detected additional class I specificities, an observation also made 
in this study. However there was complete disagreement on specificity between CDC 
and PRA-STAT for almost 50% of the samples. This could be explained by the 
presence of HLA class II specific antibodies in the samples. The results of this 
analysis have shown that class II specific antibody will cause many positive reactions 
which could be wrongly interpreted if the analysis was performed using only the class 
I types as was the case in the studies published prior to the discovery of class II 
antigen on the PRA-STAT plates. Whilst Zachary's results can easily be reinterpreted 
in the knowledge of the class II component of the test it is less clear why Kerman et al 
should have found such close agreement on antibody specificity, although a large 
contribution to the good correlation was made by the inclusion of over 300 samples 
(out of the 495 tested) which were antibody negative. It could be possible that few of 
the samples which tested positive contained any class II specific antibody, the 
majority of the samples test came from patients awaiting a first transplant although the 
study did show PRA-STAT positivity to be more common in patients with failed first 
grafts. The results of this study have found that the majority of patients with failed 
grafts who were tested by PRA-STAT do have class II specific antibody. 
Bryan et al (1995) concluded that PRA-STAT was not an appropriate method 
for the detection of class I antibody when compared with a locally produced ELISA 
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plate which used solubilised antigen from platelets. This is not surprising as 
comparison was not, as believed at the time, between equivalent methods but of a 
method where class I antigen was present on the plate with one where both class I and 
class II antigens were present. 
The reanalysis of the PRA-STAT data already collected showed that inclusion 
of the class II types into the analysis software allowed reliable detection of class II 
antibodies in addition to class I antibodies. One problem in the detection of class II 
antibodies has been the difficulty of distinguishing them from class I antibodies also 
present in the same samples. This can only be done by carrying out absorptions to 
remove the class I antibodies or by blocking antibody binding using monoclonal 
antibodies. This is a more lengthy process than conventional screening and a 
technique which allows detection of antibodies to both class I and class II at the same 
time would obviously be advantageous. It was found that in many samples this was 
possible. The analysis of antibody binding by measuring optical density provides 
detailed information on the strength of each individual reaction, especially when 
compared with the scoring systems used in CDC screening which are not only very 
subjective but also limited to only 5 or 6 broad categories for strength of reaction. 
The software allows presentation of the results sorted according to strength of 
reaction. This will often show that the reactions to one antigen produce similar 
optical density measurements so that positive results for an individual antigen will be 
grouped together when sorted according to strength. This has allowed determination 
of both class I and class II specificities in the same sample in many cases although 
there are some samples where this is still impossible, particularly in some of those 
with very high PRs. There are inevitable limitations associated with fixed panels 
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which are also encountered in CDC screening techniques. Some antigens are very 
highly represented across the panel, especially the broad DQ antigens. There are also 
some antigens where linkage disequilibrium has not been overcome, e. g. B8 is only 
found in association with DR3 and B57 with DR7. 
Despite the limitations of the technique PRA-STAT was shown to be a very 
good complimentary method to the Flowscreen already developed, allowing 
specificity determination for both the class I and class II specific antibodies detected 
by Flowscreen. The original testing of the Flowscreen had shown that the method 
was more sensitive than CDC testing, producing more positive results even when 
compared with CDC screening by CLLs which detects both class I and class II 
antibodies. The strong similarities in the antibody profiles of the patients tested post- 
transplant between PRA-STAT and Flowscreen suggested that PRA-STAT may have 
a similar level of sensitivity and could therefore be used to identify antibodies which 
are not detected by CDC in some samples which are Flowscreen positive. 
The development of the Flowscreen technique was intended to provide a 
method which was more sensitive than CDC screening and to use this method to 
investigate antibody production in patients with failed transplants. With little 
published data specifically relating to patients with failed grafts, especially with 
regards class II specific antibodies it was hoped that the Flowscreen method would 
provide more information about these patients than the existing CDC techniques used. 
The approach taken was to look at antibody development following graft failure in all 
patients over a ten year period. As well as looking at differences in the antibodies 
detected by various techniques in these patients the antibodies produced were also to 
be related to the degree of HLA matching of the failed grafts as previous studies had 
191 
produced conflicting results on the influence of matching on subsequent antibody 
production. As matching was to be investigated in this way it was also decided to 
compare matching in the functioning and failed transplants. 
Before commencing with the testing of samples from patients with failed 
grafts the results of the CDC screening were reviewed in detail. A number of patients 
produced HLA class I specific antibodies immediately following graft failure which 
were reactive with a very high proportion of the CDC panels. It was decided that 
many of these samples would not benefit from Flowscreening as the results of the 
routine Flowscreen, now well established in the laboratory, had shown that these 
patients invariably had Flowscreen PRs over 80%. It was felt that this would not 
provide any substantial additional information on these patients. All samples with 
CDC PRs of less than 50% were to be screened by Flowscreen, in addition 
Flowscreen was also to be used for a proportion of those with CDC PRs over 50% 
where the specificity was not entirely clear. The subsequent testing of PRA-STAT 
and its identification as a method for the determination of both HLA class I and class 
II specificity provided a further screening technique for analysing the samples already 
tested by Flowscreen. 
The results of the testing showed that both Flowscreen and PRA-STAT 
detected HLA specific antibodies in samples which were negative by conventional 
CDC screening. The samples were tested by Flowscreen before PRA-STAT and it 
had been initially thought that the Flowscreen positive samples which were CDC 
negative may contain HLA class II specific antibodies in many cases although the 
possibility of greater sensitivity for class I detection was also acknowledged, 
especially where samples subsequently developed CDC detectable class I specificity. 
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The PRA-STAT screening showed that in most cases both these explanations held 
true. The majority of samples tested by all 3 methods were shown to contain both 
HLA class I and class II specific antibodies, directed towards mismatched donor 
antigens. In addition PRA-STAT detected HLA class I specific antibodies which 
were not found by CDC screening. The study therefore confirmed the view that 
screening techniques with greater sensitivity than the conventional CDC screen could 
provide additional information about the antibodies produced following transplant 
failure. The ability of PRA-STAT to define antibody specificity, even in many of the 
samples with high PR, indicates that samples with CDC PRs of greater than 50% 
would benefit from PRA-STAT screening. This has not been done in this study but 
future studies should utilise PRA-STAT screening for these samples. 
In many of the cases tested where Flowscreen and PRA-STAT detected 
antibodies not shown by CDC, cytotoxic testing of subsequent samples did show an 
increase in the PR and in the specificities detected. This suggests that the antibodies 
detected by the newer methods could be low titre antibodies, although the strength of 
many of the reactions as measured by optical density in PRA-STAT would not 
altogether support this idea. It is also possible that the antibodies could be non- 
complement fixing as discussed earlier. 
Although PRA-STAT showed higher sensitivity than conventional CDC, 
Flowscreen appears to be the most sensitive technique. The high Flowscreen PRs 
could not always be accounted for by the specificities of the antibodies detected by 
pRA-STAT. This suggests that Flowscreen is detecting additional antibody. It is 
possible that this could be due to very low titre antibodies to additional HLA antigens, 
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particularly those within cross reactive groups as discussed earlier, or the antibodies 
detected may be directed at non-HLA antigens. 
There were 3 cases where Flowscreen was the only method to detect any 
antibody with no evidence of any HLA specific antibody being detected by CDC or 
PRA-STAT in any subsequent samples. In all cases the Flowscreen PRs were 
relatively low, less than 40%. Low Flowscreen PRs were also found in only 2 of 46 
patients with functioning grafts. The fact that the majority of patients with 
Flowscreen detectable antibodies do eventually develop cytotoxic antibody suggests 
that the low levels of antibody binding which are detected in a small proportion of 
patients may not be HLA specific and may not have any detrimental effect on 
transplanted kidneys as they have been found in patients with stable graft function. 
A number of studies have investigated antibody production following 
transplantation and its association with graft function. It has been shown that HLA 
specific antibody production often accompanies rejection episodes in the patients 
studied (Martin et at 1987, Tang et al 1988, Scomik et a1 1989, Halloran et al 1992). It 
has been suggested that rejection episodes which are accompanied by antibody 
production may be more severe than those where there is no evidence of antibody (Al- 
Hussein et al 1994) and the eventual outcome of these rejection more likely to be graft 
failure (Lobo et al 1995). The comparison of the Flowscreen and PRA-STAT 
methods involved investigation of antibody production in transplanted patients. It 
was found that production of antibodies which were specific for mismatched donor 
HLA antigens accompanied irreversible rejections in this small group of patients 
whereas a number of patients with no detectable antibody experienced reversible 
rejection episodes. 
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A recent study using PRA-STAT has found that rejection episodes which are 
accompanied by antibody production do not respond standard therapy whereas those 
with no PRA-STAT detectable antibody do (Nanni-Costa et al 1997) confirming 
earlier observations of the poor prognosis for rejections which are associated with 
antibody. If antibody production, whilst not predicting the onset of a rejection 
episode, is predictive of the severity of the rejection and the response to treatment it 
may be possible to use such information to modify the anti-rejection therapy 
accordingly. Routine monitoring of antibody production post transplant would be a 
time consuming, and possibly expensive, procedure which may be of use in only a 
minority of cases. The techniques developed and assessed in this study can be used to 
produce results quickly. Flowscreen can be used to rapidly screen large numbers of 
samples at very little cost. PRA-STAT can provide the essential information about 
antibody specificity. A combination of these two methods could be used to gain 
information on antibody status in patients at the onset of rejection even if regular 
monitoring were not considered possible. 
Analysis of the influence of HLA mismatching on subsequent antibody 
production tended to support the view that the greater the number of mismatched 
antigens the higher the resulting panel reactivity. This was shown to be significant 
when matching for A. B. DR was analysed but did not achieve statistical significance 
when DR matching was considered alone. This could be due to the very small 
number of fully DR matched grafts which failed. Overall 7 complete DR matched 
grafts failed, but no post transplant samples were available for screening in 2 cases (1 
cadaveric and 1 living donor transplant). Of the 5 patients who were tested 3 produced 
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no detectable antibody at any time following graft failure, the remaining 2 produced 
antibodies with PRs of 35 and 96 respectively. 
Two previous studies have produced conflicting conclusions in this area. 
Scornik et al (1987) investigated the effect of HLA-A and B match on subsequent 
antibody production following graft failure and found that there was a significantly 
higher peak PR in patients with 3 or 4 mismatched antigens than in those with 2 or 
less. Matas et al (1990) however, when looking at HLA-A, B, DR mismatching did not 
find any significant effect on subsequent antibody production. The results presented in 
Matas' study make pairwise comparisons of PR according to mismatch and there is no 
data presented which indicates whether an analysis for trend was carried out. The 
results presented in this study have shown that a trend for increasing PRs can be 
shown if the appropriate statistical analysis is performed. The study by Matas et al 
limited its investigation of antibody production to antibodies detected by CDC 
screening with peripheral blood lymphocytes, therefore it is unlikely that any class II 
specific antibodies would have been detected. 
As shown by the studies commented on above very little attention has been 
paid to the production of HLA class II specific antibodies following graft loss. This 
may be due to the lack of agreement on the clinical significance of B cell positive 
crossmatches. It has been suggested that positive B cell crossmatches which are due 
to class II specific antibodies are associated with inferior graft outcome whereas those 
which are not a result of HLA specific antibody are not (Russ et al 1987, Scornik et al 
1992, ten Hoor et al 1993, Lazda et al 1993). This study has shown that the majority 
of patients screened for class II specific antibody following graft failure were found to 
produce donor specific class II antibodies, directed at both HLA-DR and HLA-DQ. 
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This finding supports the idea that positive B cell crossmatches in patients with a 
previous failed transplant may well be a result of HLA class II specific antibody. 
The significance of the antibodies produced following graft failure on the 
outcome of subsequent transplants has been investigated. As with previous studies 
(Sanfilippo et al 1987, Matas et al 1990) it was found that a higher proportion of 
patients who never produced antibody following a failed graft were retransplanted 
compared with those who do produce detectable antibody. In the group of patients 
studied the success of second grafts was significantly higher in patients with no 
history of antibody production compared with those patients who did produce 
antibody, although the numbers analysed were small. Although the policy of the unit 
during this period had been to avoid transplanting a patient with a mismatched antigen 
if there was any evidence of an antibody specific for that antigen at some time prior to 
the crossmatch the results of the new screening techniques used suggest that the CDC 
results which were the basis of such decision taking may not have given sufficient 
information about the patients antibodies. Although there were only 3 cases where the 
pRA-STAT had clearly shown that an antibody specific for an antigen which the 
patient was subsequently mismatched for had been produced prior to that transplant 
all 3 cases failed. One of these was a class I antibody and 2 were specific for HLA- 
DQ. Whilst antibodies specific for HLA-DR have been infrequently studied, DQ 
specific antibodies have received even less attention. One report of a positive 
crossmatch due to DQ specific antibody suggested that this was not associated with 
any deleterious effects on the transplant (Taylor et al 1987). This study has shown 
that patients frequently produce both DR and DQ specific antibodies following graft 
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loss, although it is sometimes difficult to distinguish DR and DQ specificity 
separately due to the strong linkage disequilibrium between the 2 loci. 
It has been suggested that repeat class I mismatches are not harmful in regrafts 
if it can shown that the patient has never produced an antibody specific to that 
mismatched antigen (Welsh et al 1988). This study has not found any significant 
association between repeat mismatches and reduced graft outcome which supports 
the view that kidneys with repeat mismatches can be successfully transplanted. 
However when comparing HLA class II repeat mismatches these did appear to have a 
higher proportion of failures than the class I repeat mismatches, 5 of 10 class II repeat 
class II mismatches compared with 1 of 6 with a class I repeat mismatch. Cecka and 
Terasaki (1994) found that patients with repeat class II mismatches had lower 3 year 
graft survival rates than those with class I repeat mismatches. The important factor in 
the study by Welsh et al was to determine whether any antibody had been formed 
which was specific for the repeat mismatch but which was no longer detectable in the 
serum samples which were used for crossmatching. Due to the screening strategy used 
in this study not all the patients receiving repeat class II mismatches have been 
screened by PRA-STAT and so it is not clear whether there had been any class II 
specific antibody produced following the failure of the first graft in all the cases. This 
question should be studied in more detail in a larger group of regrafts comparing class 
II repeat mismatch and no repeat mismatch groups as the evidence would suggest that 
there may be an important effect of class II specific antibody on regraft outcome. 
A recent report has shown an association between HLA-DP matching and 
graft outcome in retransplants (Mytilineos et al 1997). The association between DP 
mismatches and poor graft survival was particularly strong in patients with high levels 
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of CDC detectable antibodies. This data suggests that it may be of interest to 
investigate HLA-DP specific antibodies in patients with failed transplants and to 
correlate this information with. data on repeat DP mismatches. The cell lines used in 
the PRA-STAT kits have been HLA-DP typed and the details of the DP antigens 
present on the plate are to be released by the manufacturers in a replacement for the 
SOFTSTAT programme used in this study. It should therefore be possible to carry 
out an analysis of HLA-DP specific antibodies at the same time as investigating the 
HLA-DR and DQ antibodies in more detail. 
In addition to investigating the impact of HLA matching on antibody 
production and on retransplants by way of repeat mismatching an analysis of HLA 
matching and graft survival was performed on the data collected for the study. January 
1984 was chosen as the start date for the 10 year study as this was the first full year in 
which transplanted patients received Cyclosporin immunosuppression. It was also at 
this time that HLA class II typing was becoming an established technique in the 
laboratory, with cadaveric donors being typed at the time of donation for HLA class I 
and class II antigens. 
There were a small number of failures in class II typing in the early years of 
the study, especially before the introduction of magnetic beads allowed purified B cell 
preparations to be used, however class II types were available for over 90% of donors. 
A slightly higher proportion of recipients were found not to have class II types, 
although these were generally patients with grafts which were still functioning or 
those who had died at some time following transplantation. Patients with failed grafts 
would have been class II typed when they were returned to the waiting list for a 
subsequent transplant. In order to obtain more complete matching records samples 
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were requested from patients with functioning transplants who had not been class II 
typed. Samples were taken when patients attended for a routine clinic appointment. 
A small number of patients with stable function were seen at such infrequent intervals 
that samples were not obtained during the course of the study, in addition patients 
who had died with functioning grafts could not be class II typed. Overall there was 
complete matching data available on 395 of 460 transplants. 
The matching analysis performed considered matching only for broad antigens 
rather than splits although it has been shown that matching for antigen splits is more 
advantageous that matching for broad antigens (Opelz 1988, Mytilinoeos et al 1997). 
However this approach requires relatively high resolution typing and for the 
population studied the HLA class II types were often only given at the level of the 
broad antigen, especially in the case of donors typed during the early years of the 
study. The results of the analysis show that within the population studied there was a 
significant effect of matching on graft survival, both for HLA-DR and for HLA- 
A, B, DR. These results are in agreement with many of the large studies which have 
been published. 
Failure to find a significant effect of matching has often been associated with 
single centre studies (Matas et al 1990, Hayes et al 1993), although this has not 
always been the case (Dyer et al 1989, Washburn et al 1995). In such studies the 
results may have been affected by the matching policy in operation at the centre. 
Some centres finding matching to be associated with graft survival have actively 
attempted to match donor, recipient pairs whereas other centres fmding no effect of 
matching have had very few cases which were well matched for comparison with the 
large proportion of poorly matched grafts. Throughout the 10 years which are 
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considered in this study there was no active matching policy at the transplant unit, 
with grafts being allocated primarily on the basis of negative crossmatch. Other 
factors, including HLA match, donor and recipient age, recipient waiting time and 
clinical status of the potential recipients were also taken into account. This resulted in 
a majority of patients receiving mismatches in the middle of the range from complete 
match to complete mismatch with smaller numbers at each extreme. However the 
spread was sufficient to provide a comparison which yielded a significant result. Thus 
a policy which took only slight account of the evidence regarding the benefits of HLA 
matching has produced data which confirm the view that matching confers a 
significant advantage in graft outcome. The results of the small number of living 
donor grafts performed were in agreement with some studies which have found that 
HLA matching does not provide any advantage in this group of patients (Terasaki et al 
1995, Jones et al 1994). The largest published study did however show a significant 
effect of matching in live donor grafts (Opelz 1997). With the very small number of 
live donor grafts in this study the results of the matching analysis cannot be regarded 
as significant. 
The beneficial effect of HLA matching which was found in this group of 
patients supports the practice of allocating cadaveric organs on the basis of HLA 
matching. In addition the analysis of antibody production following graft failure has 
shown that higher levels of panel reactive antibodies will result from the failure of 
poorly matched grafts compared with well matched grafts. This increased antibody 
production significantly affects both the chance of a patient receiving a regraft and the 
success of any subsequent graft. The small number of cases where HLA class II 
mismatches were repeated on regrafts provides some evidence that class II 
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mismatching may be particularly detrimental. The use of new and more sensitive 
techniques for antibody screening have demonstrated that class II specific antibodies 
are produced in many patients following failure of a class II mismatched graft. 
Routine screening for HLA class II antibodies is not undertaken in many laboratories, 
a practice which this study suggests may lead to a gap in the understanding of 
patient's antibodies. 
The use of sensitive crossmatching techniques, particularly flow cytometry, 
has meant that many transplants are not performed because of a positive crossmatch 
when the standard CDC test is negative. This practice probably detects a large 
proportion of the antibodies which this study has shown sensitive screening 
techniques will detect. However reliance on the crossmatch to detect these antibodies 
is dependant on the samples which are used for crossmatching. Whilst some centres 
will use all the stored samples from a patient many do not because of the practical 
difficulties associated with crossmatching very large numbers of samples from 
patients who have been on the waiting list for a considerable length of time. These 
laboratories will make a selection of sera for crossmatching based on the information 
screening results have supplied about the panel reactivities, specificities and antibody 
class for each sample. The results of this study suggest that the standard screening 
techniques may underestimate antibody levels in some samples and that a more 
sensitive screening technique may be advantageous. It has been stated that a 
screening technique which is as sensitive as the final crossmatch test should be 
employed (Fuller 1991). The results of this study strongly support this view and by 
using such a method indicate that the extra information provided may prove important 
in setting up and interpreting crossmatches for clinical renal transplantation. 
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Flow cytometric analysis of antibody binding to pools of CLL cells or EBV 
transformed cell lines is a sensitive and reliable method for the detection of HLA class 
I and class II specific antibodies. 
The commercially produced ELISA kit, PRA-STAT, detects both HLA class I 
and class II specific antibodies with greater sensitivity than standard 
lymphocytotoxicity screening. Antibody specificity can be determined from the 
pRA-STAT results. 
Flow cytometric and PRA-STAT screening of serum samples from patients 
with failed transplants provides information about antibody specificity and panel 
reactivity which conventional CDC screening does not provide. 
The majority of patients with failed transplants produce both HLA class I and 
class II specific antibodies. 
HLA matching for primary cadaveric renal transplantation is related to graft 
survival and failure of a poorly matched graft results in greater sensitisation as 
measured by panel reactive antibody than does failure of a well matched graft. 
There is evidence that repeating HLA class II mismatches and that pre-formed 
I-ILA class II specific antibodies may be detrimental for regrafts. This requires further 
investigation to clarify the importance of HLA class II antibodies and matching for 
second and subsequent grafts. 
Figure 6.1 illustrates a screening strategy for detecting antibody production 
and defining specificity in regularly collected samples. Using this strategy the impact 
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of antibody production following graft failure on subsequent grafts will be further 
investigated in a retrospective study. The most sensitive technique will be used as the 
first line screen. Samples which are positive by Flowscreen will be screened by both 
CDC and PRA-STAT. The use of both techniques is necessary to confirm HLA class 
I specificity as this may be difficult to do using PRA-STAT only in samples with both 
class I and class II specific antibodies because of the limitations of the fixed panel. 
The antibody specificities determined for each serum sample can be analysed by 
computer programme and additional specificities can be predicted based on epitope 
analysis. These additional specificities can be confirmed by screening selected 
samples from each individual concerned on a cell panel constructed to contain the 
antigens of interest, which are not found in PRA-STAT or the CDC panels already 
used. 
This comprehensive technique should provide detailed information on 
antibodies specific for HLA A, B, C, DR, DQ and DP. It will also be possible to 
investigate the importance of immunoglobulin class and subclass using this strategy. 
Monoclonal antibodies to the IgG subclasses, IgM and IgA are available and can be 
used in both flow cytometric and ELISA techniques. High resolution HLA typing of 
both donor and recipient may be necessary to provide sufficient detail on matching for 
a complete analysis of the data. 
The results of the study will be used to determine, in greater detail than the 
present study, the specificity, immunoglobulin classes and relationship to previous 
mismatches of antibodies which may be detrimental to regraft outcome. 
The relationship between antibody production and rejection episodes post- 
transplant will be investigated in a larger group of patients. The results will be 
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analysed to determine whether information on antibody status, available at the time of 
diagnosis of rejection, may be helpful in determining the appropraite anti-rejection 
treatment to be adminstered. 
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Samples 
(collect monthly) 
Flowscreen 
(first sample)\ 
le-101, Flowscreen 
(subsequent samples) 
PRA-STAT (class I+ II) 
pos 
CDC (class I) 
neg 5% PRA-STAT confirm neg 
PRA-STAT 
change in % PR 
CDC 
no change CDC 6 monthly 
check for IgM 
Figure 6.1 Screening strategy for detecting antibody production and 
defining HLA class I and class II specificity 
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